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Abstract  
Multiple sclerosis is one of the most common autoimmune disorders, and the leading cause of 
neurological disability in young adults in the Western world. Pathologically, multiple 
sclerosis begins with inflammatory infiltration into the brain and spinal cord, which leads to 
extensive demyelination, neuronal loss, and gliotic scars. The resultant central nervous system 
damage is responsible for the wide-ranging presentation of neurological symptoms such as 
motor and sensory deficits, vision impairment or ataxia. The active inflammatory foci are 
characterized by an initial infiltration of CD4
+
 and CD8
+
 T cells, which then orchestrate an 
inflammatory effector phase that ultimately leads to brain damage.  
 
Central to this disease pathway is the adhesion of lymphocytes to endothelial cells and the 
ultimate migration of these lymphocytes from the peripheral circulation across the blood-
brain barrier. The adhesion and transmigration of lymphocytes across the endothelium is a 
complex process involving interactions between complementary adhesion molecules on the 
surfaces of lymphocytes and endothelial cells. Following adhesion of the T cells to 
endothelial cells, the integrity of the blood-brain barrier is then compromised through 
breakdown of the tight and adherens junctions, which will then allow lymphocytes to migrate 
into the central nervous system parenchyma. Once the T cells have gained entry to the 
nervous system, they activate local microglia, which results in the production of vasoactive 
substances, chemokines, and cytokines that further attract additional peripheral leukocytes, 
triggering progressive damage. 
 
The cause of multiple sclerosis, however, is not yet fully elucidated despite considerable 
knowledge about the pathophysiology of leukocyte infiltration. While multiple sclerosis is 
incurable, several drugs modify disease progression, including beta interferons, glatiramer 
acetate, mitoxantrone, FTY720, and the monoclonal antibody, natalizumab. These drugs have 
all been shown to reduce the number of relapses, however, none of these immunomodulating 
drugs can completely protect against disease progression. Furthermore, these drugs can have 
severe side effects, such as cardiotoxicity, liver damage, acute myeloid leukemia, and 
progressive multifocal leukoencephalopathy. Thus, the identification of novel targets and the 
development of therapeutic alternatives are of the utmost importance for the treatment of 
patients with multiple sclerosis. 
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In this study, we demonstrate that the acid sphingomyelinase/ceramide pathway plays a 
central role in the development of experimental autoimmune encephalomyelitis, the animal 
model of multiple sclerosis. Using this experimental model, we show that both genetic 
deficiency and pharmacological inhibition of acid sphingomyelinase by amitriptyline protects 
against the development of central nervous system inflammatory infiltrates and typical 
clinical symptoms. Acid sphingomyelinase converts sphingomyelin into ceramide in the outer 
layer of the cell membrane, which has previously been shown to form ceramide-enriched 
membrane platforms that serve to cluster receptors upon activation, thereby permitting and 
amplifying their signal transduction. Using bone marrow transplantation and adhesion assays, 
we demonstrate that ceramide mediates clustering of -1 integrin on T lymphocytes upon 
contact with endothelial cells and thereby T lymphocyte adhesion. Inhibition of acid 
sphingomyelinase prevents lymphocyte adhesion and, thus, all subsequent pathophysiology 
including blood-brain barrier disruption, lymphocyte immigration into the parenchyma, and 
inflammation in the central nervous system. The functional blockade of the acid 
sphingomyelinase/ceramide system by the well-known antidepressant drug amitriptyline 
could be a novel therapeutic option for multiple sclerosis patients. 
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Zusammenfassung 
Die Multiple Sklerose ist eine der häufigsten Autoimmunerkrankungen und gilt in der 
westlichen Welt als Hauptursache für neurologische Behinderungen bei jungen Erwachsenen. 
Aus pathologischer Sicht entsteht die Multiple Sklerose durch entzündliche Infiltrate im 
Gehirn und Rückenmark, die zu umfangreicher Demyelinisierung, Verlust von Nervenzellen 
und gliösen Narben führen. Die hierdurch verursachten Schäden des Zentralnervensystems 
sind für die weitreichenden neurologischen Symptome, wie motorische und sensorische 
Defizite, Sehstörungen oder Ataxie, verantwortlich. Kennzeichnend für die aktiven 
Entzündungsherde sind eine anfängliche Infiltration von CD4+ und CD8+ T-Zellen, die eine 
entzündliche Effektorphase einleiten und schließlich zur Schädigung des 
Zentralnervensystems führen.  
 
Eine zentrale Rolle spielt bei der Krankheitsentstehung die Adhäsion von Lymphozyten an 
Endothelzellen sowie deren anschließende Migration aus dem peripheren Blutfluss über die 
Blut-Hirn-Schranke ins Zentralnervensystem. Die Adhäsion und Transmigration von 
Lymphozyten über das Endothel der Blut-Hirn-Schranke ist ein komplexer Prozess, bei dem 
Adhäsionsmoleküle auf der Oberfläche von Lymphozyten und Endothelzellen miteinander 
wechselwirken. Die initiale Bindung von T-Zellen an das Endothel beeinträchtigt durch einen 
Zusammenbruch von Tight Junctions und Adhärenzverbindungen die Barrierefunktion der 
Blut-Hirn-Schranke. Hierdurch wird den Lymphozyten die Einwanderung ins Hirnparenchym 
ermöglicht. Im Zentralnervensystem bewirken sie eine Aktivierung von lokalen mikroglialen 
Zellen, die wiederum die Produktion von vasoaktiven Substanzen, Chemokinen und 
Zytokinen fördern, weitere Leukozyten aus der Peripherie anziehen und somit zum 
Fortschreiten der Schädigung beitragen.  
 
Die Ursache der Multiplen Sklerose ist jedoch, trotz der beträchtlichen pathophysiologischen 
Erkenntnisse über die Leukozyteninfiltration, noch nicht vollständig geklärt. Obwohl die 
Erkrankung nicht heilbar ist, gibt es verschieden Medikamente wie Betaferon, 
Glatirameracetat, Mitoxantron, FTY720 und den monoklonalen Antikörper Natalizumab, die 
ihren Verlauf beeinflussen. Für alle diese Medikamente wurde gezeigt, dass sie die Anzahl 
der Schübe verringern, ein Fortschreiten der Krankheit jedoch nicht komplett verhindern 
können. Des Weiteren können bei der Einnahme der oben genannten Medikamente ernste 
Nebenwirkungen wie Kardiotoxizität, Leberschäden, akute myeloische Leukämie und eine 
progressive multifokale Leukenzephalopathie auftreten. Aus diesen Gründen sind die 
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Erkennung von neuen Angriffspunkten und die Entwicklung therapeutischer Alternativen von 
äußerster Wichtigkeit für die Behandlung von Patienten mit Multipler Sklerose. 
 
In dieser Studie zeigen wir, dass der Sphingomyelin/Ceramid-Reaktionsweg eine zentrale 
Rolle in der Entwicklung der Experimentellen Autoimmunen Enzephalomyelitis, dem 
Tiermodel der Multiplen Sklerose, spielt. Anhand dieses experimentellen Modells wird 
demonstriert, dass sowohl der genetische Mangel als auch die medikamentöse Hemmung der 
sauren Sphingomyelinase durch Amitriptylin vor der Entstehung entzündlicher Infiltrate im 
Zentralnervensystem und der Entwicklung der typischen klinischen Symptome schützen. Die 
saure Sphingomyelinase spaltet Sphingomyelin in der äußeren Zellmembran, wodurch 
Ceramid entsteht. In Studien wurde bereits gezeigt, dass die hierdurch gebildeten Ceramid-
angereicherten- Plattformen zur Clusterbildung aktivierter Rezeptoren dienen, wodurch deren 
Signaltransduktion ausgelöst und verstärkt wird. 
 
Mit Hilfe von Knochenmarkstransplantation und Adhäsionsassays zeigen wir, dass Ceramid 
die Bildung von -1 Integrin-Clustern auf T-Lymphozyten, nach deren Kontakt mit 
Endothelzellen, vermittelt und damit die Lymphozytenadhäsion ermöglicht. Entsprechend 
verhindert eine Hemmung der sauren Sphingomyelinase die Adhäsion und damit alle 
folgenden Pathomechanismen, wie die Schädigung der Blut-Hirn-Schranke, die 
Einwanderung von Lymphozyten in das Hirnparenchym und die Entzündung des 
Zentralnervensystems. Die funktionelle Blockade des Sphingomyelin/Ceramid-Systems durch 
das bekannte Antidepressivum Amitriptylin könnte eine neue Therapieoption für Patienten 
mit Multipler Sklerose darstellen. 
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1 Introduction 
1.1 MS overview 
Multiple sclerosis (MS) is the most common inflammatory disorder of the central nervous 
system (CNS) and a leading cause of disability in young adults (Milo and Kahana, 2010). It is 
estimated that the total number of people worldwide living with this disorder is 2-2.5 million. 
MS was first described by Jean-Martin Charcot (Fig. 1.1) in 1868 and was, in fact, called 
Charcot disease until 1921 (Clanet, 2008). Throughout his career (1848-1893), Charcot saw 
around 30 cases of MS and thought that it was a rare disorder, with a propensity for females, 
though he noted that the incidence was increasing with improved diagnostic accuracy.  
 
 
 
Figure 1.1 Jean-Martin Charcot (1825-1893). Images from the History of Medicine, National 
Library of Medicine (public domain). 
 
Since its first description in the mid-1800’s as a rare neurologic condition, the diagnosis of 
MS has significantly increased to an incidence of 0.7-8.7 per 100,000/year and a prevalence 
of 1-287 per 100,000 people, depending on geographic location (Rosati, 2001). The pattern of 
disease is unevenly distributed throughout the world and increases progressively with 
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geographic latitude: its prevalence varies from <5 cases per 100,000 people in tropical 
areas/Asia and >100-200 cases per 100,000 people in temperate regions including Canada, the 
United States, northern Europe and New Zealand (Fig. 1.2).  
 
 
Figure 1.2 Multiple sclerosis prevalence geographic distribution (Milo and Kahana, 2010). 
 
There is also uneven gender distribution; as noted by Charcot, there is a higher prevalence of 
females with MS worldwide (female/male ratio around 2:1) and an even greater difference has 
been noted in select populations, specifically Canada where the female/male ratio is 3:1 
(Orton et al., 2006). 
 
Clinical symptoms typically present between 20-50 years of age, with a peak at 30 years of 
age. MS patients present with a variety of neurological signs and symptoms attributed to 
white matter lesions disseminated in time and space, and may occur in sudden attacks or as 
insidious neurologic progression. Common presenting symptoms can include paresthesias, 
incoordination, motor weakness, monocular visual disturbances (optic neuritis), diplopia, 
vertigo, and dizziness (Compston and Coles, 2008). These symptoms may also be 
accompanied by other signs including fatigue, sexual dysfunction, urinary retention or 
urgency, pain, cognitive dysfunction, ataxia or Lhermitte’s phenomenon (an electrical 
sensation running down the back to the limbs on neck flexion). This list is not exhaustive, and 
patients have a large variability in presentation. 
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The clinical course of MS is highly variable. Approximately 85% of patients will present with 
a relapsing-remitting (RRMS) course characterized by sudden attacks of neurological signs 
and symptoms followed by complete or partial recovery lasting from days to months and 
separated by periods of stable neurological condition without clinical disease activity (Milo 
and Kahana, 2010). The other 10-15% will present with a primary-progressive (PPMS) course 
characterized by a steady accumulation of neurological disability from disease onset. Some of 
these patients may have superimposed relapses, which is then classified as a progressive-
relapsing (PRMS) course. Eventually, 65% of patients originally presenting with RRMS will 
convert to a secondary progressive (SPMS) disease course (Compston and Coles, 2008). The 
mean reduction in life expectancy is 5-10 years, representing a median time to death of 30 
years from disease onset (Bronnum-Hansen et al., 2004). However, it is important not to 
forget the impact of this disease on patient mental health, as it has been demonstrated that 
patients with MS have an increased lifetime frequency of depression of up to 50% and a 
greater risk of suicide (Minden and Schiffer, 1990). 
 
The diagnosis of MS is based on an evolving set of criteria, called the McDonald Criteria, 
most recently updated in 2011 (Polman et al., 2011). This clinical guideline takes into account 
medical history, clinical neurological exam, MRI, visual evoked potential and spinal fluid 
analysis. Patients are assessed for past or current presence of an attack, defined as patient-
reported or objectively observed events typical of an acute inflammatory demyelinating event 
in the CNS, current or historical, with duration of at least 24 hours, in the absence of fever or 
infection. When the patient has experienced 2 or more attacks with objective clinical evidence 
of a lesion and dissemination in space demonstrated by ≥1 T2 lesion in at least 2 of 4 MS-
typical regions of the CNS (periventricular, juxtacortical, infratentorial, or spinal cord), and 
all other diagnoses have been ruled out, a diagnosis of MS can be made with reliable 
accuracy. When there is only evidence of 1 attack, or there is insidious neurological 
progression suggestive of MS, then the criteria to demonstrate dissemination in space and 
time as well as presence of positive CSF findings, including isoelectric focusing evidence of 
oligoclonal bands and/or elevated IgG index, must be utilized to make a diagnosis. It should 
be noted that before a definite diagnosis of MS can be made, at least 1 attack must be 
corroborated by findings on neurological examination, visual evoked potential response in 
patients reporting prior visual disturbance, or MRI consistent with demyelination in the area 
of the CNS implicated in the historical report of neurological symptoms. 
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The cause of MS is not conclusively known, though it is believed to be multifactorial in 
nature. The main factors thought to contribute to MS are environment, genetics, and infection. 
A number of environmental factors have been implicated in an increased risk of MS including 
organic solvents and dental amalgam, but the factor most likely associated with MS 
susceptibility is sunlight exposure mediating vitamin D synthesis and ultraviolet radiation. 
This hypothesis would generally explain the geographical distribution, as the more northern 
cultures would have less sun exposure and thus less vitamin D synthesis. While vitamin D 
supplementation has been shown to be inversely associated with MS risk and will even 
suppress EAE in an experimental model, it is not certain whether it is the vitamin D levels 
alone or the combination of vitamin D with UV exposure that is protective (Milo and Kahana, 
2010).  
 
Epstein-Barr virus (EBV) infection has also been implicated in the pathogenesis of MS and, 
in fact, follows a similar geographic distribution. Populations with early EBV exposure (a 
high proportion of seropositivity pre-adolescence) have a decreased risk of MS compared to 
populations with late exposure (Ascherio and Munger, 2007). There is also evidence to 
implicate genetic factors in MS pathogenesis; twin studies have shown a concordance rate of 
25-30% and an index of heritability of 0.25-0.76 in monozygotic twins (Hawkes and 
Macgregor, 2009). Furthermore, about 20% of MS patients have at least one affected relative 
and the risk for developing MS in first-degree relatives is increased 3.4-5.13% (Dyment et al., 
1997). Likewise, there is a 10-fold increased risk in children from parents who both have MS. 
These studies point to a genetic susceptibility, and not a mendelian inheritance pattern, but the 
precise genes involved have not yet been elucidated. Based on the current research, the 
pathogenesis of MS is likely multifactorial and dependent upon environmental factors 
including vitamin D, UVR, EBV infection and a genetic predisposition. 
 
Although there is no cure for MS, there are a number of disease-modifying therapies in use 
that can mitigate progression of the disease. These agents include glatiramer acetate (Johnson 
et al., 1995), interferon (IFN) -1a (Jacobs et al., 1996), IFN -1b (Paty and Li, 1993), the 
monoclonal antibody, natalizumab (Polman et al., 2006) and, more recently, the sphingosine-
1-phosphate (S1P) receptor modulator, FTY720 (Kappos et al., 2010). However, these drugs 
can have severe side effects associated with their usage including bradycardia, and resultant 
asystole, in the case of FTY720 (Espinosa and Berger, 2011) and progressive multifocal 
leukoencephalopathy (PML) in the case of natalizumab (Sorensen et al., 2012). These severe 
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conditions and the numerous other negative ramifications including influenza symptoms, 
opportunistic infections, liver damage, etc. limit the ability to use these drugs in the clinical 
setting and prompts the need to continue the search for more effective treatment strategies 
with fewer side effects. 
 
1.2 Pathophysiology 
MS is generally thought to be an immune-mediated disorder, though the exact sequence of 
events that leads to demyelination is not completely understood. There is a large degree of 
heterogeneity in clinical presentation, MRI and pathologic progression such that one 
underlying mechanism may not be fully responsible, but instead a number of factors that 
influence the outcome. Chronic MS lesions are characterized by the demyelinated plaque, 
consisting of a well-demarcated hypocellular area with loss of myelin, relative preservation of 
axons and astrocytic scars (Noseworthy et al., 2000). These chronic lesions are often round or 
oval, and occasionally follow the path of blood vessels creating what are called “Dawson’s 
fingers” (Fig 1.3). 
 
 
Figure 1.3 Dawson’s Fingers on MRI. Sagittal T2-weighted image in a patient with long-standing 
MS showing multiple periventricular plaques (Dawson's fingers) adjacent to the corpus callosum. 
Thalamus (arrow) and juxtacortical white matter (arrowheads) are also affected (Pretorius and 
Quaghebeur, 2003). 
 
Inflammatory infiltrates in the CNS are generally perivascular with some parenchymal 
diffusion and are primarily composed of macrophages and lymphocytes (Noseworthy et al., 
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2000). However, in order to understand the underlying mechanism of MS, it is important to 
assess the role of the blood-brain barrier, lymphocyte adhesion and subsequent transmigration. 
 
Since the late 1800’s, the brain has been considered a privileged organ; insulated from the rest 
of the body. Starting from the early work of Paul Ehrlich, a German physician, who reported 
in 1885 that the brain and spinal cord did not stain when a dye was injected into the vascular 
system of mice (Ribatti et al., 2006). In 1900, Lewandowsky introduced the term “blood-brain 
barrier” (BBB) following experiments where dye was injected into the cerebrospinal fluid 
(CSF) resulting in parenchymal staining, thus overcoming some “barrier”. Further work in the 
early 1920’s by Shirai in Japan and Murphy and Sturm with rat sarcoma, revealed that the 
brain was protected from normal immune responses, later termed “immunological privilege” 
by Billingham and Boswell (Galea et al., 2007). This privilege allowed tissue grafts, bacteria, 
viruses and vectors to evade immune recognition when delivered into the brain parenchyma. 
However, although peripheral immune access is certainly restricted and well controlled, we 
now know that the central nervous system (CNS) is capable of and subject to inflammatory 
responses to a variety of insults (Rivest, 2009). 
 
The CNS is able to maintain its immuno-privileged status, mostly due to restriction of 
peripheral leukocyte trafficking from the periphery to the CNS through the BBB. The BBB 
(Fig 1.4) is composed of endothelial cells, astrocytes, basement membrane and junctional 
proteins (Persidsky et al., 2006).  
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Figure 1.4 Schematic of blood-brain barrier (BBB). 
 
Astrocytes are an integral component of the BBB and envelop >99% of the BBB endothelium 
(Hawkins and Davis, 2005). The presence of tight junctions is also a key feature of an intact 
BBB, and includes: occludin, the claudins and junctional adhesion molecules (Persidsky et al., 
2006). Under normal conditions, leukocyte entry is kept to a low level because autoreactive 
naïve T cells undergo negative selection and apoptosis. However, in MS, for whatever reason, 
these autoreactive cells do not apoptose and have the potential to attack the CNS, effecting 
autoimmune responses against myelin components through molecular mimicry, bystander 
activation and epitope spreading (Fujinami et al., 2006).  
 
In order to study the pathologic mechanisms behind MS, scientists have assessed an animal 
model designated as experimental autoimmune encephalomyelitis (EAE). Since its discovery 
in 1933 (Rivers et al., 1933), it has been used to replicate MS and acute disseminated 
encephalomyelitis (ADEM) in a variety of animal models, particularly rodents. The EAE 
model consists of two phases: 1) T cell priming and activation in the periphery, and  2) an 
effector phase with migration of leukocytes across BBB, local reactivation and invasion into 
CNS parenchyma (Becher et al., 2006). The migration of T cells across the BBB is a complex 
interaction between adhesion molecules on the surface of lymphocytes and endothelial cells 
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(Engelhardt and Ransohoff, 2005). T cell migration is thought to proceed with the following 
progression (Fig 1.5): 
1.) T cell rolling mediated by -4 integrins and P-selectin glycoprotein ligand-1 (Kerfoot 
and Kubes, 2002) 
2.) Homeostatic chemokines (e.g. CCL19 and CCL21) produced by endothelial cells 
likely mediate T cell activation through G-protein coupled receptors (GPCRs) (Alt et 
al., 2002) 
3.) Firm adhesion via ICAM-1 and VCAM-1 on endothelial cells interacting with LFA-1 
and 41 on lymphocytes (Laschinger et al., 2002).  
4.) T cell crawling and transmigration (Schenkel et al., 2004). 
5.) CD4+ T cells accumulate in perivascular spaces, and encounter specific antigens on 
antigen presenting cells (APCs) which reactivates the lymphocytes (Greter et al., 
2005). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Schematic of lymphocyte adhesion/transmigration. The multi-step model of lymphocyte 
adhesion and transmigration across the blood-brain barrier endothelium in spinal cord white matter 
(Engelhardt, 2006). 
 
T cells that have crossed into the CNS parenchyma then activate local microglia which 
produce vasoactive substances, chemokines and cyto- and myelinotoxic cytokines attracting 
peripheral lymphocytes and damaging brain tissue (Frohman et al., 2006). Cytokines 
including TNF, IL-1, IL-2, LT, LT and IFN are upregulated in the cerebrospinal fluid 
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(CSF) and brain tissue of MS patients (Kunz and Ibrahim, 2009) and some of these cytokines 
modulate phospholipid and sphingolipid metabolism (Plo et al., 1999).  
 
1.3 Acid sphingomyelinase 
Sphingomyelinases are a family of enzymes that catalyze the breakdown of sphingomyelin 
into ceramide by cleavage of the phosphorylcholine linkage (Fig 1.6). The first 
sphingomyelinase was discovered in 1940 by Thannhauser and Reichel (Thannhauser S J, 
1940), and several more have been discovered since then, differing in tissue distribution and 
pH optimum. Acid sphingomyelinase (Asm) was first clearly described by Gatt (Gatt, 1963) 
and the deficiency of which was subsequently found to be responsible for Niemann-Pick 
disease (Type A and B); a rare, autosomal recessive inherited lysosomal storage disorder 
(Brady et al., 1966). The gene for Asm is called SMPD1, and is found on chromosome 
11p15.4; the gene encodes a 629 amino acid polypeptide (Schuchman et al., 1992). It has both 
a lysosomal form (75 kDa) and a secreted form (57 kDa) (Ferlinz et al., 1994).  
 
 
Figure 1.6 Formation of ceramide from sphingomyelin via acid sphingomyelinase (Seto et al., 
2004). During the creation of ceramide from sphingomyelin, a phosphorylcholine is released as a by-
product. 
 
Asm is a zinc metalloprotein and the secreted form requires exogenous zinc for full activity 
(Schissel et al., 1996) as well as removal of the terminal cysteine residue (Qiu et al., 2003). 
Asm in vitro has an optimum pH of 4.5-5, and some studies have shown acidified 
microenvironments at the cell surface linking these microenvironments and lipid 
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microdomains, which is where Asm is active (Ro and Carson, 2004). The secreted form of 
Asm is able to be fully active in LDL particles at physiologic pH (Schissel et al., 1998). Asm 
releases ceramide in the outer layer of the cell membrane from sphingomyelin (major pathway 
of ceramide generation, see Fig 1.7 and 1.8) allowing formation of ceramide-rich 
microdomains which fuse to form rafts which can re-organize cell signaling proteins, cluster 
receptor molecules and amplify signals (Gulbins and Li, 2006). 
 
 
Figure 1.7 Ceramide pathway (Henry et al., 2011). Ceramide can be synthesized de novo from 
palmitoyl-CoA or through the conversion of sphingomyelin via sphingomyelinase. Ceramide can also 
be created via ceramidase (salvage pathway). 
 
Activation of Asm, and subsequent release of ceramide, was demonstrated after stimulation 
with numerous interventions including CD95, TNF receptor, irradiation, UV-light, and 
treatment with chemotherapeutic drugs (doxorubicin, cisplatin, gemcetabine). However, it is 
also activated upon stimulation with CD28, CD40, CD14, CD5 and LFA-1. CD40 ligation 
results in Asm moving from internal cell stores to the extracellular surface of the plasma 
membrane where it acts to produce ceramide from sphingomyelin, resulting in ceramide rich 
domains (Grassme et al., 2002a). Furthermore, genetic deficiency of Asm prevents CD40 
clustering and cell signaling pathways, a result which can also be produced by the 
neutralization of ceramide (Grassme et al., 2002b). Asm is also activated by stimulation of T 
cells with CD28 and results in impaired IL-2 secretion when cells are genetically deficient 
(Stoffel et al., 1998). Asm inhibition, whether through genetic deficiency, pharmacologic 
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inhibition or siRNA, provides protection against stimuli that would normally cause apoptosis 
including ischemia (Yu et al., 2000), radiation (Paris et al., 2001), and chemotherapy 
(Dimanche-Boitrel et al., 2005).  
 
The majority of pharmacologic inhibitors of Asm belong to a class of drugs called “FIASMAs” 
(Functional inhibitor of acid sphingomyelinase) as defined by Kornhuber et al. in 2010 
(Kornhuber et al., 2010). These drugs are weak organic bases and include desipramine 
(Kolzer et al., 2004), fluoxetine, sertraline and amitriptyline (Kornhuber et al., 2008), as well 
as many others. It is thought that these drugs inactivate Asm indirectly by causing the release 
of the enzyme from the inner membrane of the lysosome (Kolzer et al., 2004) resulting in 
inactivation through proteolytic degradation (Hurwitz et al., 1994). 
 
1.4 Sphingolipids in Multiple Sclerosis 
Much of what we know in this field has only been discovered in the last 15 years and remains 
a veritable treasure trove for future studies and developments. However, although there is still 
much to learn, progress in the understanding and treatment of multiple sclerosis has already 
taken place. From the clinical setting it has been shown, through lipid microarray analysis, the 
presence of anti-sphingomyelin antibodies in the CSF of MS patients (Kanter et al., 2006). 
The role of sphingolipids in multiple sclerosis is complex, acting on diverse mechanisms such 
as apoptosis (Jana and Pahan, 2007), T cell trafficking (Goetzl and Graler, 2004), astrogliosis 
(Wu et al., 2008), and receptor clustering (Grassme et al., 2002b).  
 
1.4.1 Leukocyte activation and trafficking 
Leukocyte activation is a crucial event in protective and adaptive immunity and is involved in 
the maintenance of self-tolerance. Although entry of leukocytes into the CNS is low under 
normal circumstances, pathologic conditions can increase trafficking. During T cell activation, 
antigen is processed and presented by antigen presenting cells to T lymphocytes through 
MHC molecules, which bind to the T cell receptor. The receptor ligation causes formation of 
lipid rafts and aggregation of co-stimulatory ligands resulting in a structural 
dependent/associated mechanism for promoting immune cell signaling (Luo et al., 2008). 
Specifically, stimulation of T cells via CD28 (an important co-stimulatory receptor) causes 
the activation of Asm and release of ceramide (Boucher et al., 1995).  
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LFA-1, a key adhesion molecule, also triggers release of ceramide, possibly through Asm 
(Rosenman et al., 1993). Ceramide released by neutral sphingomyelinase (NSM) is also 
involved in the stimulation of lymphocytes via the adhesion molecule, L-selectin (Phong et al., 
2003). Additionally, the production of ceramide in endothelial cells triggers upregulation of 
Weibel-Palade bodies (Bhatia et al., 2004) resulting in increased expression of P-selectin 
(Babich et al., 2009), which promotes adhesion of leukocytes to endothelial cell layers (Burns 
et al., 1999). These studies show that the sphingolipid pathway is highly involved in the 
activation and adhesion of leukocytes. 
 
Interestingly, treatment of MS patients with fluoxetine, a functional inhibitor of Asm 
(Kornhuber et al., 2008), has been shown to reduce the MRI lesion progression in a clinical 
trial (Mostert et al., 2008). Furthermore, it has been demonstrated that the S1P receptor is 
important for emigration of lymphocytes from both thymus and peripheral lymphoid organs 
(Goetzl and Rosen, 2004). FTY720 downregulates S1PR1 expression in lymphocytes by 
inducing internalization, and degradation of the receptor, thereby resulting in lymphocyte 
sequestration (Oo et al., 2011). Kappos et al. (Kappos et al., 2006) reported that 
administration of FTY720 in MS patients reduced the number of lesions on MRI and clinical 
disease severity. 
 
1.4.2 Pro-inflammatory mediators 
Many chronic CNS diseases, acute CNS injuries, some psychiatric disorders and aging CNS 
are associated with a progressively spreading inflammation and marked oxidative stress 
(Lucas et al., 2006). Specifically, chronic neuroinflammatory disorders (such as multiple 
sclerosis) are associated with elevated levels of proinflammatory cytokines (Kunz and 
Ibrahim, 2009), chemokines, cell adhesion molecules, proinflammatory enzymes such as 
inducible nitric oxide synthase (iNOS) and cyclooxygenase (Jana and Pahan, 2010). This 
chronic neuroinflammation results in sustained release of inflammatory mediators, which 
perpetuates a vicious cycle of glial activation and further release of factors. These 
inflammatory mediators (cytokines, eicosanoids, etc.) and reactive oxygen species are largely 
responsible for the degeneration of neuronal cells (Barth et al., 2012). The proinflammatory 
molecule, TNF, has been highly associated with neuroinflammatory diseases, especially MS 
(Bielekova and Martin, 2004). Stimulation of the TNF receptor activates Asm (Schneider-
Brachert et al., 2004) and Mg
2+
-dependent NSM, and the resulting sphingomyelin hydrolysis, 
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rather than de novo synthesis, was the predominant source of ceramide increases in a primary 
cortical neuronal cell line (Barth et al., 2012). 
 
Additionally, persistent glial activation and increased proinflammatory cytokine levels lead to 
BBB disruption, transvascular leakage and lymphocyte migration through upregulation of cell 
adhesion molecules (ICAM-1, VCAM-1 and selectin) expressed on BBB endothelium. Thus, 
regulation of the release of these factors could lead to promising therapies in the field of 
neuroinflammation.  
  
Dissertation: The Role of Acid Sphingomyelinase in Experimental Autoimmune Encephalomyelitis 
18 
 
2 Aim of this work 
While much progress has been made in the development of drugs for MS, it is still not 
possible to completely control MS and many of the currently available drugs have serious side 
effects that prohibit their use in some patients. It is of the utmost importance that we continue 
to search for treatments that will prevent relapses without the associated side effects. To this 
end, we chose to study the Asm enzyme due to the role of ceramide (the enzymatic end-
product) in receptor clustering and the ability to inhibit Asm activity with pharmacologic 
agents, specifically amitriptyline, that have minimal side effects and have been in clinical use 
for more than 50 years. 
 
The aim of this study was to identify the role of Asm in MS pathophysiology and elucidate 
the cellular and molecular mechanisms mediated through this enzyme pathway. In detail, we 
aimed to answer the following questions: 
 
1. How does loss of Asm function, either through genetic knockdown or pharmacologic 
inhibition, affect clinical outcome? 
2. How does Asm affect lymphocyte and endothelial cell activity? 
3. How does Asm affect the molecular pathways and expression within these cell types? 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Instruments 
Instrument Source 
Accu-Jet Pipette Controller  BrandTech Scientific, Essex, USA 
Autoclave V-150, V-2540EL  Systec, Wettenberg, Germany 
Axiovert 25 inverted microscope  Carl Zeiss Microscopy, Jena, Germany 
Biofuge 13 Centrifuge  Heraeus, Hanau, Germany 
Eclipse TS100 Inverted Microscope  Nikon Instruments Inc., Melville, USA 
Electric Heatable, Forceps for Safer Transfer of Tissue 
Specimens Leica EG F  
Leica Microsystems Nussloch GmbH, 
Nussloch, Germany 
Eclipse E600 fluorescence microscope  Nikon, Alzenau, Germany 
Epson perfection V700 photo scanner  Epson, Munich, Germany 
FACSCanto™ II Flow Cytometer  BD Biosciences, San Jose, USA 
Fixed-angle rotor for Optima MAX series ultracentrifuge MLA-
130, TLA-100.3, TLA-100 
 Beckman Coulter, Fullerton, USA 
Forced-air laboratory freezer  Liebherr, Ochsenhausen, Germany 
Forced-air laboratory refrigerator  Liebherr, Ochsenhausen, Germany 
General Rotator, STR4  Stuart Scientific, Staffordshire, UK 
HERAcell CO2 incubator  Heraeus, Hanau, Germany 
HERAcell 150i CO2 Incubator  Thermo Scientific, Langenselbold, 
Germany 
Heraeus HERAsafe HS 12 biological safety cabinet (Class II)  Heraeus, Hanau, Germany 
Heraeus function line heating and drying ovens Heraeus, Hanau, Germany 
HERAfreeze -86C freezer  Heraeus, Hanau, Germany 
Ice machine  Eurfrigor Ice Makers Srl, Lainate, Italy 
Incubation hood TH30 and Universal shaker SM30  Carl Roth GmbH, Karlsruhe, Germany 
Laboratory balance ALS120-4, EW4200, EW420  Kern & Sohn, Balingen, Germany 
Laboratory centrifuge SIGMA 4K15C  Sigma Laborzentrifugen GmbH, Osterode 
am Harz, Germany 
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Laboratory pH meter InoLab pH 720  WTW, Weilheim, Germany 
Leica SM 2000 R Sliding Microtome  Leica Microsystems Nussloch GmbH, 
Nussloch, Germany 
Leica TP1020 Tissue Processor  Leica Microsystems Nussloch GmbH, 
Nussloch, Germany 
Leica EG1150C Cold plate  Leica Microsystems Nussloch GmbH, 
Nussloch, Germany 
Leica EG1150 H Heated Paraffin Embedding Module  Leica Microsystems Nussloch GmbH, 
Nussloch, Germany 
Leica TCS SP5 Confocal microscope  Leica Microsystems Nussloch GmbH, 
Nussloch, Germany 
Leica TCS SL software program, version 2.61  Leica, Mannheim, Germany 
Liquid scintillation counter  Beckman Coulter, Krefeld, Germany 
Micro-plate reader  TECAN, Sunrise Remote, Männedorf, 
Switzerland 
Magnetic stirrer  Ika-Combimag RCO, Namur, Belgium 
Microscope Zeiss Axio Scope  Carl Zeiss, Göttingen, Germany 
MLA-130 Rotor, Fixed Angle, Titanium for Ultracentrifuge  Beckman Coulter, Brea, USA 
Multiband UV table  Peqlab, Karlsruhe, Germany 
Multipette® plus  Eppendorf, Hamburg, Germany 
Nanodrop ND-1000 spectrophotometer  Peqlab, Karlsruhe, Germany 
Nuaire IR AutoFlow NU-2700E Water-Jacketed CO2 Incubator  Plymouth, MN 
Pipette PIPETMAN P2, P20, P200, P1000  Gilson, Villiers le Bel, France 
Pipette Single-Channel 2μl-20μl, 10μl-100μl, 100μl-1,000μl  Eppendorf, Hamburg, Germany 
Pipette Pipetus  Hirschmann, Eberstadt, Germany 
Platform shaker Duomax 1030  Heidolph, Schwabach, Germany 
Precision Balance scale  Sartorius, Goettingen, Germany 
Sigma 4K10 bench top centrifuge  Sigma Laborzentrifugen GmbH, Osterode 
am Harz, Germany 
SmartSpecÔ3000 Spectrophotometer  Bio-Rad Laboratories, Hercules, USA 
Sonopuls HD2070  Bandelin Electronic, Berlin, Germany 
Stretching Table OTS 40  MEDITE GmbH, Burgdorf, Germany 
Super High pressure Mercury Lamp Power supply  Nikon, Alzenau, Germany 
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Thermoblock TDB-120  BioSan, Riga, Latvia 
Thermomixer Comfort  Eppendorf, Hamburg, Germany 
Ultra-pure water purification system PURELAB Ultra  ELGA, Celle, Germany 
Ultracentrifuge Optima MAX 130,000 rpm  Beckman Coulter, Fullerton, USA 
UV/visible spectrophotometer Ultrospec3100pro  Amersham Biosciences, Munich, 
Germany 
Vortex Genie 2  Scientific Industries, Bohemia, USA 
Vortex-Shaker Reax 2000  Heidolph, Schwabach, Germany 
Water bath  Köttermann GmbH & Co KG, Hänigsen, 
Germany 
 
3.1.2 Experimental materials 
Material Source 
Assistent® 12mmø Microscope cover glasses  Glaswarenfabrik Karl Hecht KG, Sondheim, 
Germany 
BD Falcon™ FACS tubes  Becton, Dickinson and Company, Heidelberg, 
Germany 
BD Falcon™ Serological pipet, 5ml, 10ml, 25ml  Becton, Dickinson and Company, Heidelberg, 
Germany 
BD Plastipak syringe, 1ml  Becton, Dickinson and Company, Heidelberg, 
Germany 
Biosphere filter tips 10ml, 100ml, 1000ml  Sarstedt, Nürnbrecht, Germany 
Bottle Top Filter 500ml, 0.22mm  Sarstedt, Nürnbrecht, Germany 
Cell strainer with 70µm nylon mesh, Sterile  BD Biosciences, San Jose, USA 
Chamber slide  VWR, Darmstadt, Germany 
Combination cap  Fresenius Kabi AG, Homburg, Germany 
Combitips (plus) 5ml, 10ml, 12.5ml  Eppendorf, Hamburg, Germany 
Cover glasses  Assistant, Sondheim, Germany 
Cover slips 10 ´ 10 mm  Marienfeld, Lauda-Königshofen, Germany 
Cryopure tubes for cell freezing  Sarstedt, Nümbrecht, Germany 
CST beads  BD Biosciences, Durham, USA 
Dako pen  Dako, Glostrup, Denmark 
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Falcon round-bottom tubes 14 ml  BD Biosciences, San Jose, USA 
Filter cassette  Perkin Elmer Inc., Rodgau, Germany 
Filter mat  Perkin Elmer Inc., Rodgau, Germany 
Glass fibre filter 90x120 mm  Perkin Elmer Inc., Rodgau, Germany 
Homogenizer  Hartenstein, Würzburg, Germany 
Immersion Oil "Immersol" 518 F fluorescence free  Carl Zeiss, Göttingen, Germany 
Isoflurane  Baxter, Unterschleißheim, Germany 
Laboratory glassware  Schott, Mainz, Germany 
Luerlock syringe 1 ml  BD Biosciences, Durham, USA 
Microscope slides 76 ´ 26 mm  Gerhard Menzel, Braunschweig, Germany 
Multiwell cell culture plate, 6well, 12well, 24well, 
48well, 96well  
Falcon, Becton Dickinson labware, Franklin Lakes, 
NJ 
Nalgene “Mr Frosty” freezing container  Thermoscientific, Novodirect GmbH, Kehl/Rhein, 
Germany 
Needle microlance 21G, 24G, 25G  B.Braun, Melsungen AG 
96-well microtest plates  Sarstedt, Nürnbrecht, Germany 
Neubauer Chamber  Hartenstein, Würzburg, Germany 
15 ml, 50 ml, round bottom 50 ml conical centrifuge 
tubes  
Sarstedt, Nürnbrecht, Germany 
Parafilm M all-purpose laboratory film  Pechiney Plastic Packaging, Chicago, USA 
Pasteur pipettes plain glass  VWR International, Leicestershire, UK 
pH-indicator Strips pH 0 - 14 universal indicator  Merck, Darmstadt, Germany 
Pipette tip 10 µl, 200 µl, 1000 µl  Sarstedt, Nürnbrecht, Germany 
Safe-Lock micro test tube 2.0 ml  Eppendorf, Hamburg, Germany 
SafeSeal micro tube 1.5 ml  Sarstedt, Nürnbrecht, Germany 
Sterile insulin syringe 1ml  Becton, Dickinson and Company, Heidelberg, 
Germany 
Surgical Blades, sterile  B Braun, Tuttlingen, Germany 
Syringe filter 0.22 µm   Carl Roth, Karlsruhe, Germany 
Syringe, 2ml, 5ml, 10ml, 20ml  B Braun, Tuttlingen, Germany 
Thickwall Polycarbonate 1ml 11×34mm Tubes for 
Ultracentrifuge  
Beckman Coulter, Brea, CA 
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Tissue culture flask, PE Phenolie style cap, 75cm², 
175cm²  
Sarstedt, Nürnbrecht, Germany 
Tissue culture dish 100×20mm  Sarstedt, Nürnbrecht, Germany 
Tissue culture dish 60×15mm  BD Falcon, BD Biosciences, Durham, USA 
Transwell  VWR, Darmstadt, Germany 
TruCount tubes  BD Biosciences, Durham, USA 
 
3.1.3 Experimental kits and systems 
Vectastain Elite ABC kit Rat IgG (Vectastain, Linearis, Wertheim-Bettingen, Germany) 
 
3.1.4 Chemicals, reagents and customized services 
Chemical/reagent Source 
(3-Aminopropyl) triethoxysilane Sigma-Aldrich Chemie, Steinheim, 
Germany 
[
14
C]sphingomyelin (Bovine; [Choline-Methyl-14C],10µCi (370kBq)) Perkin Elmer, Rodgau, Germany 
0.05%Typsin EDTA Invitrogen, Darmstadt, Germany 
2-mercaptoethanol Sigma-Aldrich Chemie, Steinheim, 
Germany 
2-methyl butane Sigma-Aldrich Chemie, Steinheim, 
Germany 
2-Propanol Carl Roth, Karlsruhe, Germany 
3
H-Thymidine Perkin Elmer, Rodgau, Germany 
Acetic acid VWR, Darmstadt, Germany 
Acetone Hedinger, Stuttgart, Germany 
Acid sphingomyelinase Sigma-Aldrich Chemie, Steinheim, 
Germany 
Amino-ethylcarbazol (AEC) Sigma-Aldrich Chemie, Steinheim, 
Germany 
Amitriptyline Sigma, Schnelldorf, Germany 
Ammonium chloride Sigma-Aldrich Chemie, Steinheim, 
Germany 
Antibiotic-antimycotic Invitrogen, Darmstadt, Germany 
Aquatex Merck, Darmstadt, Germany 
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Brefeldin A Sigma-Aldrich Chemie, Steinheim, 
Germany 
Calcium chloride Carl Roth, Karlsruhe, Germany 
Casein Merck, Darmstadt, Germany 
Chloroform p.A. Applichem, Darmstadt, Germany 
Concanavalin A Sigma-Aldrich Chemie, Steinheim, 
Germany 
Coomassie brillant blue G 250 Carl Roth, Karlsruhe, Germany 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich Chemie, Steinheim, 
Germany 
Dimethylformamide Sigma-Aldrich Chemie, Steinheim, 
Germany 
Dulbecco’s Modified Eagle Medium (DMEM) (High Glucose) Invitrogen, Darmstadt, Germany 
EDTA Carl Roth, Karlsruhe, Germany 
EGTA Carl Roth, Karlsruhe, Germany 
Entellan Merck, Darmstadt, Germany 
Eosin Y (aqueous) Merck, Darmstadt, Germany 
Ethanol Sigma-Aldrich Chemie, Steinheim, 
Germany 
Evans Blue dye Sigma-Aldrich Chemie, Steinheim, 
Germany 
Fetal bovine serum-South America PAN Biotech GmbH, Aidenbach, 
Germany 
Fibronectin Roche, Mannheim, Germany 
Formamide Sigma-Aldrich Chemie, Steinheim, 
Germany 
Giemsa Merck, Darmstadt, Germany 
Glucose Merck, Darmstadt, Germany 
Glutamax Invitrogen, Darmstadt, Germany 
Glutardialdehyde Carl Roth, Karlsruhe, Germany 
Glycerol Carl Roth, Karlsruhe, Germany 
H2O2 (30%) Otto Fishar GmBH, Saarbrueken, 
Germany 
HBSS Sigma-Aldrich Chemie, Steinheim, 
Germany 
HEPES Carl Roth, Karlsruhe, Germany 
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HEPES Sigma-Aldrich Chemie, Steinheim, 
Germany 
Hydrochloric acid Carl Roth, Karlsruhe, Germany 
IGEPAL CA-630 Sigma-Aldrich Chemie, Steinheim, 
Germany 
Incomplete Freund Adjuvant DIFCO Laboratories, Michigan 
Ionomycin Sigma-Aldrich Chemie, Steinheim, 
Germany 
Isopropanol Hedinger, Stuttgart, Germany 
KCL Merck, Darmstadt, Germany 
Laminin Sigma-Aldrich Chemie, Steinheim, 
Germany 
liquid scintillation cocktail for proteins, peptides and nucleic acids 
(Ready Protein
+
) 
Beckman Coulter, Krefeld, Germany 
Magnesium chloride Carl Roth, Karlsruhe, Germany 
Manganese (II) chloride Sigma-Aldrich Chemie, Steinheim, 
Germany 
Mayers Hematoxylin  VWR, Darmstadt, Germany 
Methanol Carl Roth, Karlsruhe, Germany 
Methanol JT Baker, Griesheim, Germany 
MgSO4 · 7 H2O Sigma-Aldrich Chemie, Steinheim, 
Germany 
Mowiol Sigma-Aldrich Chemie, Steinheim, 
Germany 
Mycobacterium tuberculosis H37 Ra  BD Biosciences, Durham, USA 
Myelin Oligodendrocytic peptide 35-55  Charite, Berlin, Germany 
N,N-Dimethylformamide Sigma-Aldrich Chemie, Steinheim, 
Germany 
Paraformaldehyde (PFA) Sigma-Aldrich Chemie, Steinheim, 
Germany 
Pepsin Solution Digest-AU Invitrogen, Darmstadt, Germany 
Pertussis toxin  Enzo life Sciences, Lörrach, 
Germany 
Phorbol-12-myristate-13-acetate Sigma-Aldrich Chemie, Steinheim, 
Germany 
PLP (139-151) Anaspec, Fremont, USA   
RPMI 1640 Medium Invitrogen, Darmstadt, Germany 
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Saponin Sigma-Aldrich Chemie, Steinheim, 
Germany 
Sodium acetate Sigma-Aldrich Chemie, Steinheim, 
Germany 
Sodium azide Sigma-Aldrich Chemie, Steinheim, 
Germany 
Sodium bicarbonate Merck, Darmstadt, Germany 
Sodium carbonate Sigma-Aldrich Chemie, Steinheim, 
Germany 
Sodium chloride Carl Roth, Karlsruhe, Germany 
Sodium citrate Sigma-Aldrich Chemie, Steinheim, 
Germany 
Sodium hydroxide Carl Roth, Karlsruhe, Germany 
Sulfamethoxazole Sigma, Schnelldorf, Germany 
Tissue Tek  Sakura Finetech Europe, Netherlands 
Trimethoprim Sigma, Schnelldorf, Germany 
Tris HCl  Merck, Darmstadt, Germany 
Trypan Blue Sigma-Aldrich Chemie, Steinheim, 
Germany 
TWEEN 20 Carl Roth, Karlsruhe, Germany 
TWEEN 20 Sigma-Aldrich Chemie, Steinheim, 
Germany 
Xylol Hedinger, Stuttgart, Germany 
Zinc chloride  Sigma-Aldrich Chemie, Steinheim, 
Germany 
 
3.1.5 Media 
3.1.5.1 Antibiotics 
Trimethoprim  Trimethoprim 100 mg 
0.2 mg/ml Dissolved in 500 ml sterile H2O. 
Sulfamethoxazole Sulfamethoxazole 500 mg 
1 mg/ml 
Dissolved in Trimethoprim solution above and used as drinking 
water in autoclaved water bottles. 
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3.1.5.2 Media for cell culture 
bEnd3 medium Dulbecco’s Modified Eagle Medium 
(DMEM; High Glucose) 
445 ml 
 Fetal bovine serum (56 C water bath, 30 
min inactivated) 
50 ml 
 Antibiotic-antimycotic (100×) 5  ml 
 Filtered with 0.22 m bottle Top Filter. Stored at 4 C 
 
MAM medium Dulbecco’s Modified Eagle Medium 
(DMEM; High Glucose) 
457 ml 
 Fetal bovine serum (56 C water bath, 30 
min inactivated) 
25 ml 
 Antibiotic-antimycotic (100×) 5  ml 
 HEPES (1M) 12.5 ml 
 Filtered with 0.22m bottle Top Filter. Stored at 4 C 
 
T Cell medium RPMI 1640Medium 435 ml 
 Fetal bovine serum (56 C water bath, 30 
min inactivated) 
50 ml 
 Antibiotic-antimycotic (100×) 5 ml 
 Glutamax 10 ml 
 Filtered with 0.22 m bottle Top Filter. Stored at 4 C 
 
3.1.6 Antibodies 
Antigen Usage (Dilution) Species Type Source 
Mouse anti-1 
integrin 
FACS (0.25 µl/2x10
5
 
cells) 
Rat PE labelled monoclonal BD Pharmingen 
Biosciences, Durham, 
USA 
Mouse anti-7 
integrin 
FACS (0.25 µl/2x10
5
 
cells) 
Rat PE labelled monoclonal BD Pharmingen 
Biosciences, Durham, 
USA 
Mouse anti-
ceramide 
Cell culture Rat Clone S58-9 Glycobiotech, Kükels, 
Germany 
Mouse anti-
CD4 
IHC (1:50) Rat Monoclonal BD Pharmingen 
Biosciences, Durham, 
USA 
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Mouse anti-
CD4 
FACS (0.4 µl/2x10
5
 
cells) 
Rat FITC-labelled 
monoclonal 
BD Pharmingen 
Biosciences, Durham, 
USA 
Mouse anti-
CD8 
IHC (1:50) Rat Monoclonal BD Pharmingen 
Biosciences, Durham, 
USA 
Mouse anti-
CD8a 
FACS (1 µl/2x10
5
 
cells) 
Rat PerCP-labelled 
monoclonal 
BD Pharmingen 
Biosciences, Durham, 
USA 
Mouse anti-
CD45 
IHC (1:50) Rat Monoclonal BD Pharmingen 
Biosciences, Durham, 
USA 
Mouse anti-
Claudin 5 
IHC (5-10 g/ml) Mouse Monoclonal Invitrogen, Darmstadt, 
Germany 
Mouse F4/80 IHC (1:100) Rat Monoclonal Serotec, Düsseldorf, 
Germany 
Mouse IgG2aκ IHC (1:100) Rat Monoclonal IQ products, Groningen, 
Netherlands 
Mouse IgG2bκ IHC (1:100) Rat Monoclonal IQ products, Groningen, 
Netherlands 
Mouse anti-
INF 
FACS (0.5 µl/2x10
5
 
cells) 
Rat PE-labelled monoclonal BD Pharmingen 
Biosciences, Durham, 
USA 
Mouse anti-
GMCSF 
FACS (0.5 µl/2x10
5
 
cells) 
Rat PE-labelled monoclonal BD Pharmingen 
Biosciences, Durham, 
USA 
Mouse anti-IL2 FACS (0.5 µl/2x10
5
 
cells) 
Rat PE-labelled monoclonal BD Pharmingen 
Biosciences, Durham, 
USA 
Mouse anti-IL4 FACS (0.5 µl/2x10
5
 
cells) 
Rat PE-labelled monoclonal BD Pharmingen 
Biosciences, Durham, 
USA 
Mouse anti-
IL17 
FACS (0.25 µl/2x10
5
 
cells) 
Rat APC-labelled 
monoclonal 
eBioscience, Frankfurt, 
Germany 
Zona 
occludins-1 
IHC (2-5 g/ml) Rabbit Polyclonal Invitrogen, Darmstadt, 
Germany 
anti-Rat IgG; 
Cy3 F(ab’)2 
Frag 
IHC (1:1000) Donkey Cy3-labelled polyclonal Dianova, Jackson 
Immunoresearch, 
Hamburg, Germany 
anti-rabbit IgG; 
F(ab’)2 
fragment  
IHC (1:100- 1:800) Donkey Cy3-labelled polyclonal Dianova, Jackson 
Immunoresearch, 
Hamburg, Germany 
anti-mouse 
IgM; F(ab’)2 
fragment 
IHC (1:100- 1:800) Donkey Cy3-labelled polyclonal Dianova, Jackson 
Immunoresearch, 
Hamburg, Germany 
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3.1.7 Cell lines 
Designations Growth Properties Organism Cell Type Source 
bEnd.3 Adherent Mus musculus  
 
Brain endothelial-
polyoma middle T 
antigen transformed 
ATCC, Wesel, 
Germany 
 
3.2 Methods 
3.2.1 Mice  
All animal experiments were performed in compliance with the German Guide for the Care 
and Use of Laboratory Animals. Female SJL mice were obtained from Charles River 
Laboratories (Sulzfeld, Germany) at the age of 6-8 wk. Female acid sphingomyelinase-
deficient (Asm -/-; protein: Asm, gene symbol: Smpd1) and female C57Bl6/J mice were 
obtained from our breeding facility. The genotype of the mice was confirmed by polymerase 
chain reaction (PCR) prior to experimentation. 
 
3.2.2 Immunization, clinical scoring guide and treatment protocols 
3.2.2.1 MOG emulsion preparation 
The emulsion used for immunization was prepared by combining MOGaa35-55 with 10 mg/ml 
CFA in a 1:1 (vol/vol) ratio in a latex-free syringe, for an end concentration of 300 g 
MOG/200 l. The solution was mixed manually with a pipette for 1 min and put on ice. The 
solution was then homogenized using a probe sonicator for 60 sec (2 cycles, 45% power) and 
again put on ice for 1 min. The sonication was repeated as previous and then frozen at -20 C 
for 24 h. After 24 h, the emulsion was thawed and the 2 cycles of sonication (as described 
above) were repeated. The emulsion was either injected immediately or stored at -20 C for 
up to one week. 
 
For the SJL EAE model, the same procedure for the emulsion preparation was used as 
described above, but with PLP aa139-151 emulsified in 4 mg/ml CFA, for an end concentration 
of 50 µg PLP/200 l. 
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3.2.2.2 Immunization 
Induction of active EAE in 6-8 wk old mice was achieved by injecting 200 l of the MOG 
(Asm -/- and wt mice) or PLP (SJL mice) emulsion, as prepared above, subcutaneously into 
the axillary and inguinal lymph node regions (50 l/lymph node region). On days 0 and 2, 300 
ng pertussis toxin dissolved in PBS up to a volume of 200 l was injected intra-peritoneally 
(i.p.).  
 
3.2.2.3 Clinical scoring guide 
Clinical disease was checked daily and scored as previously described (Engelhardt et al., 
1997):  
- 0.5: Limp tail 
- 1: Hind leg weakness  
- 2: Hind leg paraparesis.  
- 3: Hind leg paraplegia and incontinence 
- 4: Fore limb and hind leg paresis.  
- 5: Death 
 
3.2.2.4 Amitriptyline treatment protocol 
Beginning on days 0 or 10 post-immunization (p.i.) and continuing for the duration of the 
experiment, 25 mg/kg amitriptyline dissolved in sterile distilled water was injected i.p. every 
12 h. The bi-daily (b.i.d.) dosing schedule was chosen to maintain a constant plasma level of 
amitriptyline. Sterile distilled water was used as the control. 
 
3.2.2.5 Bone marrow transplantation 
Asm -/- recipient mice (6 wk old) were exposed to 10 Gy whole-body irradiation given as 
split doses of 2  5 Gy with a 4 h interval using a linear accelerator (-source). Donor bone 
marrow cells (1 x 10
7
 per mouse) derived from wt mice were then injected, via the tail vein, 
into each recipient. Transplanted mice were housed in autoclaved cages and treated with 
antibiotics in drinking water (0.2 mg/ml trimethoprim and 1 mg/ml sulfamethoxazole) for 3 
wk after irradiation. 
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3.2.3 Tissue collection 
Mice were anesthetized with isoflurane and perfused through the left heart ventricle with 4% 
paraformaldeyde; spinal cord was harvested, and either dehydrated for paraffin embedding or 
placed in Tissue Tek and snap-frozen in isopentane with liquid nitrogen at -80 C for cryo-
sectioning. The frozen tissue was cut serially in 6 m sections on a cryostat microtome and 
fixed with acetone at -20 C. Paraffin embedded tissue was serially cut at 0.5-6 m on a 
microtome. Both frozen and paraffin-embedded tissue sections were placed on silanized slides 
to ensure adherence during staining protocols. The protocol for slide silanization was as 
follows: 
- 3 dips in Acetone 
- 1 min in 5% (v/v) Silane in Acetone 
- 3 dips in Acetone 
- 3 dips in dH20 
- dry 24 h in 37 C incubator 
 
3.2.4 Assessment of vascular leakage 
Evans Blue dye (EBD; 12.5 mg/kg) was administered intravenously (i.v.) in Asm -/- and wt 
mice at the peak of disease and allowed to circulate for 4 h before the mice were put to death. 
These mice were perfused through the left ventricle with 10 ml PBS to remove intravascular 
dye, then the spinal cord was either taken for quantitative analysis using fluorescence 
detection or fixed overnight in 4% PFA then snap frozen in Tissue Tek. 30 m sections were 
taken on the cryostat microtome, air-dried and acetone fixed for 2 min. The sections were 
dipped in xylol and cover-slipped with Entellan.  
 
3.2.5 Fluorescent detection of Evans Blue dye 
Quantitative evaluation of EBD was performed on the spinal cord of both Asm -/- and wt 
immunized mice at the peak of disease. Spinal cord samples were weighed (SCW), 
homogenized in 250 l formamide and incubated for 24 h at 37C. The samples were then 
centrifuged at 5000 x g for 30 min. The absorption (A) of EBD in the spinal cord supernatant 
was measured at 620 nm. The concentration of EBD in the spinal cord was then determined 
against a standard curve and calculated with the equation: ngEBD = 22.411(A620) - 0.4165. 
The degree of vascular leak in each spinal cord is presented as the amount of EBD/weight of 
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spinal cord (ngEBD/mg). Experiments were performed in collaboration with the group of Dr. 
E. Gulbins.  
 
3.2.6 Histology 
3.2.6.1 Basic stains 
Hematoxylin and Eosin staining was performed on spinal cord of wt and Asm -/- mice. The 
protocol used was performed exactly as described in the Mayer’s Hematoxylin protocol from 
Sigma: 
1. Deparaffinize to water or fix and hydrate frozen sections.  
2. Stain in Mayer’s Hematoxylin Solution for 15 min  
3. Rinse in warm running tap water for 15 min 
4. Place in distilled water for 30 sec 
5. Place in Eosin Y Solution (aqueous) counterstain for 30–60 sec 
6. Dehydrate and clear through 2 changes each of 95% Reagent Alcohol, absolute 
Reagent Alcohol, and xylene (2 min each) 
7. Mount with Entellan. 
 
3.2.6.2 Immunohistochemistry 
Immunohistochemistry for CD45, CD4, CD8 and F4/80 was performed on frozen serial 
sections using a three-step immunoperoxidase technique in a humidified chamber exactly as 
described previously by Walter et al. (Walter et al., 2002): 
1. Thaw tissue for 10 min in a dehydration chamber 
2. Fix in acetone -20 °C for 10 min 
3. Let dry in fume hood 
4. Wash in 1x PBS for 5 min 
5. Block in 0,2% Casein for 45 min 
6. In humidified chamber, put 100 l primary antibody (in PBS 0,1% Tween 20), or 
Isotype control (in PBS 0,1% Tween) on tissue encircled with a DAKO pen for 1 h 
at RT 
7. Wash in PBS 0,1% Tween 20 for 5 min 
8. In humidified chamber, put 100 µl AK Goat-anti-rat Biotin from Vectastain kit 
(use 5µl in 1 mL of PBS for dilution) for 30 min 
9. Wash in PBS 0,1% Tween 20 for 5 min 
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10. In humidified chamber, put 100 µl Strep-HRP from Vectastain kit for 30 min 
11. Wash in PBS 0,1% Tween for 5 min 
12. Put 100 µl AEC dye solution (100 µl AEC dissolved in dimethylformamide (8 
mg/ml)/1,4 mL AEC buffer (7,9 mL Na Acetate (0,1 M) + 2,1 mL Acetic acid (0,1 
M))/1,5 µl H2O2) on tissue until red (approximately 3-10 min) 
13. When tissue is ready, pour off AEC into waste container and stop reaction with 
PBS 
14. Counterstain with Mayer’s Hematoxylin, approximately 1 min, until tissue is 
purple 
15. Rinse with dH20 x 3 and tap water x 3 until water is clear and let sit approximately 
20 min 
16. Coverslip with Aquatex 
 
Immunohistochemistry for tight junctions, including Zona occludins-1 (ZO-1) and claudin-5, 
was performed on paraffin sections of spinal cord. Paraffin sections were dewaxed, washed in 
H20, blocked in H/S supplemented with 5% FCS, washed in PBS, incubated with Pepsin for 
12 min, washed in PBS and incubated with anti-ZO-1 antibodies or anti-claudin-5 antibodies 
for 45 min in H/S + 5% FCS. Samples were washed 3-times in PBS supplemented with 0.5% 
Tween 20 and once in PBS, incubated for 45 min with Cy3-conjugated antibodies diluted 
1:1000 in H/S + 5% FCS. Samples were washed again 3-times in PBS/0.05% Tween 20 and 
once in PBS, embedded in Mowiol and analysed by confocal microscopy. Experiments were 
performed in collaboration with the group of Dr. E. Gulbins. 
 
3.2.7 bEnd.3 cell culture  
The brain endothelial cell line (bEnd.3) used for the experiments were cultured and sub-
cultured as per the recommendation from ATCC. The cells were grown in bEnd.3 complete 
growth medium in an incubator at 37 °C and 5% carbon dioxide (CO2). When the flasks were 
full and ready to subculture, culture medium was removed and discarded. The cell layer was 
rinsed with 0.25% (w/v) Trypsin-0.03% (w/v) EDTA solution to remove all traces of serum 
(which contains trypsin inhibitor). Then 5 ml of Trypsin-EDTA solution was added to each 
flask and the cells observed under an inverted microscope until the cell layer just began to 
detach. 5 ml of complete growth medium was then added and the cells aspirated by gently 
pipetting. Cell suspensions were collected in 50 ml falcon tubes and centrifuged for 8 min 
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(1200 rpm). The supernatant was removed and the cells resuspended in new growth medium 
to create a subcultivation ratio of 1:2 to 1:4 (5 ml/flask). The medium was renewed every 2-3 
days and subcultivated every 7 days. To freeze cells for preservation, cells were collected 
from 2-3 flasks and suspended in freezing medium (complete growth medium, 95%; DMSO, 
5%) in a cryotube. Cryotubes were placed in a “Mr Frosty” freezing container at -80 C for 
24-48 h, then stored permanently in liquid nitrogen vapor. 
 
3.2.8 In vitro adhesion assay 
Determination of adherence of lymphocytes to an endothelial mono-layer  was performed as 
described by Reiss et al. (Reiss et al., 1998). Briefly, 16 well chamber slides were coated with 
50 g/ml fibronectin and then plated with bEnd.3 cells (2x104/ well) for 2 days prior to the 
experiment. T lymphocytes were obtained by homogenizing mouse axillary, inguinal and 
mesenteric lymph nodes in a HBSS/10% FCS/1% HEPES solution and strained through a 
70m cell filter. Cell suspensions were centrifuged (1200 rpm, 8 min, 4 C) and re-suspended 
in MAM medium. T cells (3x10
5
 cells/well in MAM medium) were co-incubated with the 
endothelial cells for 40 min at 4 C on a rocking shaker. Following co-incubation, non-
adherent T cells were washed off with PBS and the slides fixed in 2.5% glutardialdehyde for 
2 h. Assays were counted with a light microscope following the fixation period. The 
following substances were tested: 10 M amitriptyline (30 min pre-incubation at RT), 1 U/ml 
acid sphingomyelinase (30 min pre-incubation at RT) and 1 mmol Mn2+ (co-incubation with 
bEnd.3 cells) All experiments were done in the presence of 10 M ZnCl and performed in 
duplicate. 
 
Dissertation: The Role of Acid Sphingomyelinase in Experimental Autoimmune Encephalomyelitis 
35 
 
 
Figure 3.1 Adhesion assay method diagram.  
 
3.2.9 In vitro transmigration assay 
In-vitro analysis of T cell transmigration through an endothelial mono-layer was performed as 
described by Rohnelt et al. (Rohnelt et al., 1997). Briefly, the filter from a Transwell double 
chamber system was coated with 50 µg/ml laminin and following a 30 min incubation time at 
RT, bEnd.3 cells (5x10
4
/well) were plated and incubated (37 ºC, 10% CO2) for 2 days. At the 
time of the assay, 600 µl MAM medium was added to the lower compartment and 100 µl 
containing 1x10
6
 lymphocytes was aliquoted to the upper compartment for 4h incubation at 
37 ºC. Following the co-incubation, the medium from the lower compartment was removed 
and transferred to TruCount tubes to be analysed by flow cytometry to determine the number 
of migrated cells. The filters were washed with PBS then fixed in a formaldehyde-saturated 
chamber overnight and stained with Giemsa to verify a confluent bEnd.3 layer. All 
experiments were done in the presence of 10 M ZnCl and performed in duplicate. 
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3.2.10 Proliferation assay 
On day 10 p.i., T cells were isolated and cultured in a 96 well plate (2x10
5
/well) in re-
stimulation medium (T cell medium/0.1% 2-mercaptoethanol), 2.5 µg/ml Concanavalin A or 
MOG antigen. The cells were cultured for 48 h at 37 ºC. Following incubation, cells were 
pulsed with 
3
H-Thymidine (1 µCi/well) and incubated for a further 16 h at 37 ºC. Cells were 
then transferred onto a glass fibre filter for measurement of tritiated thymidine by a liquid 
scintillation counter. Means and SEM were calculated from duplicate or triplicate wells. 
 
3.2.11 Surface and intracellular expression of adhesion molecules and cytokines 
For extracellular antibody staining, 2x10
5
 T cells (day 14 p.i.) were washed and re-suspended 
in FACS buffer (1x PBS/ 4% FCS/ 0.4% sodium azide). Anti--1 integrin or anti--7 integrin 
was then added along with anti-CD4 and anti-CD8a to determine the number of positive cells 
within the T cell population from the sample. Cell surface staining was performed with the 
appropriate combination of antibodies conjugated to fluorescein isothiocyanate, 
allophycocyanin, phycoerythrin, and peridinin-chlorophyll protein complex. The antibody/cell 
suspension was incubated at 4 C for 40 min then washed and analyzed by flow cytometry 
with FACScanto using the FACS Diva Software. 
 
For cytokine staining, 2x10
5
 cells were incubated at 37 C for 4 h in T cell medium with 500 
ng/ml Ionomycin, 50 ng/ml Phorbol-12-myristate-13-acetate (PMA) and 10 µg/ml Brefeldin 
for stimulation. Following the incubation period, the cells were permeabilized with 0.1% 
Saponin for the intracellular cytokine staining. The cells were then incubated at RT for 30 min 
with anti-interleukin-2 (IL-2), anti-IL-4, anti-IL-17, anti-interferon- (IFN) or anti-
granulocyte macrophage colony-stimulating factor (GMCSF) along with anti-CD4 and anti-
CD8a. The cells were then washed and analyzed as above. 
 
3.2.12 Ceramide clustering 
To determine the clustering of β1-integrin with ceramide rafts on the cell surface of T cells, 
we used confocal microscopy of T cells co-incubated with a bEnd.3 monolayer. Two days 
before the assay, 1×10
5
 bEnd.3 cells were plated on glass coverslips in a 24-well plate. On 
day 14 p.i., T cells were harvested from wt and Asm -/- mice as described above, and 5×10
5
 T 
cells were co-incubated with the bEnd.3 monolayer for 5, 10, 15, or 20 min. The cells were 
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removed, pelleted and fixed in 4% PFA for 15-min. After fixation, the slides were washed in 
PBS and blocked in HEPES/Saline (H/S; 132 mM NaCl, 20 mM HEPES [pH 7.4], 5 mM KCl, 1 
mM CaCl2, 0.7 mM MgCl2, 0.8 mM MgSO4) supplemented with 5% FCS and 0.05% Tween 20 
for 10 min. Anti-ceramide antibody clone S58-9 was diluted 1:100 in H/S + 1% FCS and cells 
were incubated for 45 min with the anti-ceramide antibody. Cells were then washed 3 times in 
PBS, incubated for 45 min with Cy3-coupled donkey anti-rabbit IgG or anti-mouse IgM 
F(ab)2 fragments, washed again three times in PBS, resuspended in 5 l of PBS, pipetted onto 
a glass slide and embedded in Mowiol. Immunofluorescence was measured with the Leica 
TCS SL software program, version 2.61. Experiments were performed in collaboration with 
the group of Dr. E. Gulbins. 
 
3.2.13 Acid sphingomyelinase activity 
In order to determine the successful transplantation of wt bone marrow in Asm -/- mice, at the 
time of sacrifice, spleen was harvested from each animal and homogenized to a single cell 
suspension. Spleen cells were pelleted and lysed in 250 mM sodium acetate (pH 5.0), 1% 
NP40, and 1.3 mM EDTA for 5 min. Lysates were diluted to 250 mM sodium acetate (pH 
5.0), 0.1% NP40, and 1.3 mM EDTA and incubated with 50 nCi per sample 
[
14
C]sphingomyelin for 30 min at 37 °C. The sphingomyelin was dried prior to the assay, 
resuspended in 250 mM sodium acetate (pH 5.0), 0.1% NP40, and 1.3 mM EDTA and bath-
sonicated for 10 min. The reaction was stopped by the addition of 800 µL 
chloroform/methanol (2:1, v/v), phases were separated by centrifugation and radioactivity of 
the aqueous phase was measured by using liquid scintillation counting to determine the 
release of [
14
C]phosphorylcholine from [
14
C]sphingomyelin as a measure of Asm activity. 
Experiments were performed in collaboration with the group of Dr. E. Gulbins. 
 
3.2.14 Statistics 
Data in figures are presented as mean + SEM. One-way ANOVA followed by Tukey’s HSD 
post hoc test was used for multiple comparisons. Two-independent samples t test was used to 
compare means for two groups. All statistical analysis was performed on GraphPad Prism for 
Windows (GraphPad software, La Jolla, CA). Statistical significance was set at p < 0.05. 
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4 Results 
4.1 Asm deficiency protects against EAE development 
To determine whether Asm plays a role in the development of EAE, we immunized Asm -/- 
and C57BL/6 wt mice with MOG35-55 in complete Freund’s adjuvant (CFA) followed by two 
injections of pertussis toxin. The wt animals exhibited clinical symptoms from day 10 p.i., 
starting with limp tail and hind-leg paresis. The disease peaked at day 19 with a mean clinical 
score of 2 and maximum clinical score of 5 (death). In contrast, all Asm-deficient animals 
exhibited no or very mild clinical symptoms, with a limp tail score of 0.5 at maximum even 
after prolonged observation (up to day 30 p.i.). Daily clinical scoring of the percentage of 
symptomatic mice showed a significant difference between wt and Asm -/- groups starting 
from day 14 and continuing to day 22 (p ≤ 0.05, t-test), after which point all the mice from the 
wt group had been sacrificed for ethical reasons (Fig. 4.1). 
 
 
Figure 4.1 Genetic Asm deficiency prevents active EAE over a 25-day period. Mice were 
immunized with MOG35-55 in complete Freund’s adjuvant (CFA). Animals were evaluated daily for 
clinical symptoms. The data show that deficiency of Asm afforded protection against developing 
symptoms of EAE. There was a significant difference in % symptomatic mice from day 14-22 (p ≤ 
0.05, t-test). Shown are means +SEM of 9 wt and 7 Asm -/- mice. 
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Further, wt mice developed an EAE-typical weight loss and only regained 0.63 +/- 0.72 g 
(mean +/- SEM) at day 25; Asm-deficient mice were resistant to weight loss and gained 2.56 
+/- 0.62 g (mean +/- SEM) by day 25 (Fig. 4.2).  
 
 
Figure 4.2 Genetic Asm deficiency prevents weight-loss associated with active EAE induction. 
Mice were immunized and weighed daily. The data show that deficiency of Asm afforded protection 
against developing weight-loss associated with EAE. The starting weight of wild-type mice and Asm-
/- mice were not significantly different (p ≥ 0.05, t-test), while the final weight of the Asm -/- mice 
was significantly higher (p ≤ 0.05, t-test). Shown are means + SEM of 9 wt and 7 Asm -/- mice. 
 
Further analysis of a large number of immunized wt and Asm-deficient mice that were used in 
experiments described below to investigate lymphocyte functions and histology changes in 
the central nervous system, confirmed the results of these kinetic studies and showed that 
93% of the wt mice exhibited symptoms up to grade 5, whereas 89% of the Asm-deficient 
animals were unaffected and 11% developed only mild clinical symptoms (Fig. 4.3). The 
average clinical score of the wt mice was 1.6 +/- 0.15 (mean +/- SEM). 
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Figure 4.3 Genetic Asm deficiency prevents active EAE. Mice were immunized for various 
experiments and evaluated for clinical symptoms at the time of sacrifice. The data show that 
deficiency of Asm afforded protection against developing symptoms of EAE. Shown are means + 
SEM of 59 wt and 28 Asm -/- mice (*p ≤ 0.05, t-test). 
 
The clinical resistance of Asm-deficient mice to EAE was associated with the absence of 
inflammatory infiltration in spinal cord, as determined by CD45 staining (Fig. 4.4), whereas 
wt mice exhibited a prominent infiltration with CD45, CD4, CD8 and F4/80 positive 
leukocytes in the spinal cord (Fig. 4.4 and 4.5). 
 
 
Figure 4.4 Genetic Asm deficiency protects against leukocytic infiltration into central nervous 
system tissue. Asm -/- and wt mouse spinal cord frozen sections (6 m) were stained with CD45 to 
assess infiltration of leukocytes. The left panel (wt) reveals characteristic leukocytic infiltration in a wt 
mouse spinal cord sacrificed at peak of disease. The right panel (Asm -/-) shows the lack of cellular 
infiltration in the spinal cord of an Asm deficient mouse taken at the same time point. These images 
are representative of all mice in the study. 
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Figure 4.5 Characteristic inflammatory infiltrates composed of predominantly T cells. 
Immunohistochemical staining of frozen sections (6 m) revealed characteristic cellular infiltrates in 
the spinal cord of wt mice. The majority of the cells stained positively for CD45 (a leukocyte marker) 
with CD4 staining as the major subset of T cells. There was also positive staining of cells for CD8 and 
F4/80 (a macrophage marker). These results are typical for EAE and are representative of multiple 
samples. 
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4.2 Asm deficiency preserves BBB integrity and tight junctions in EAE 
BBB breakdown is one of the main pathophysiological features resulting in inflammatory 
infiltration with clinical symptoms in EAE. In order to elucidate the influence of Asm on the 
BBB integrity, we injected Evans Blue into MOG immunized wt and Asm deficient mice. We 
observed a massive Evans Blue intraparenchymal leakage in wt but not in Asm-deficient mice 
(Fig. 4.6). Through quantitative analysis, we were also able to show a significantly decreased 
leakage of Evans Blue dye in Asm -/- mouse spinal cord (Fig. 4.7). 
 
 
Figure 4.6 BBB integrity remains intact in Asm deficient mice. Evans Blue dye (12.5 mg/kg) was 
injected i.v. at the peak of disease. Spinal cord frozen sections (30 m) were analyzed under 
fluorescence microscopy and revealed significant leakage of Evans Blue dye in wt mice with no 
leakage in Asm -/- mice. Non-immunized control mouse shown for comparison. 
 
 
Figure 4.7 BBB integrity is significantly more compromised in wt compared to Asm deficient 
mouse spinal cord. Evans Blue dye was injected i.v. at peak of disease. Spinal cord was isolated, 
homogenized and assessed for quantitative analysis of intraparenchymal Evans Blue dye by 
spectrophotometry. Non-immunized control mice (n=3) are shown for comparison. The amount of 
Evans Blue dye in Asm -/- spinal cord was significantly less than the amount quantified in wt mouse 
spinal cord, and wt nil control was significantly less than either of the experimental groups (*p ≤ 0.05, 
one-way ANOVA). Values are shown as mean + SEM from 5 wt mice and 5 Asm -/- mice. 
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The notion that Asm deficiency protects from disruption of the BBB during EAE is also 
supported by the finding that tight junctions remain intact in Asm-deficient EAE immunized 
mice but are disrupted in EAE immunized wt mice, as indicated by the degradation of ZO-1 
and Claudin-5 (Fig. 4.8).  
 
 
Figure 4.8 Tight junction integrity is maintained in Asm-deficient mice. Immunofluorescence 
staining for claudin-5 (Panel A-C) and ZO-1 (Panel D-F) revealed tight junction breakdown in wt (A 
& D) spinal cord, while Asm -/- (C & F) mice had intact tight junctions. Non-immunized wt control (B 
& E) is shown for comparison. 
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4.3 Asm in lymphocytes is sufficient to induce EAE 
To further differentiate the importance of endothelial versus lymphocytic Asm in EAE 
development, we irradiated Asm-deficient mice with 10 Gy and transplanted them with bone 
marrow from syngenic wt mice. Control studies measuring Asm activity in the spleen 
confirmed successful bone marrow transplantation. Immunization of these mice with MOG35-
55 and pertussis toxin resulted in a severe EAE up to grade 2 indicating that Asm-expression 
in lymphocytes is sufficient to induce EAE (Fig. 4.9). The clinical data was corroborated with 
histology, and showed leukocyte infiltration in Asm -/- mice transplanted with wt bone 
marrow cells (Fig. 4.10). 
 
 
Figure 4.9 Bone marrow transplantation of wt cells into Asm deficient mice confers 
susceptibility to EAE disease. Asm -/- mice were irradiated with 10 Gy and transplanted with wt 
bone marrow cells (1 x 10
7
 per mouse). The recipient mice were immunized with MOG following 
bone marrow reconstruction and scored daily. The Asm -/- recipient mice (wt donor cells) became as 
clinically ill as wt control, with no significant difference in peak clinical score (p ≥ 0.05, t-test). 
Values presented are mean + SEM for 5 Asm -/- recipient mice. 
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Figure 4.10 Bone marrow transplantation of wt cells into Asm deficient mice abolishes 
protection against leukocytic infiltration. Immunohistochemical analysis of spinal cord with CD45 
corroborates the clinical findings after bone marrow transplantation and reveals inflammatory 
infiltrates in Asm -/- recipient mice that have been reconstructed with wt bone marrow. Images are 
representative of 5 Asm -/- recipient mice. 
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4.4 Asm does not control lymphocyte proliferation, integrin or cytokine 
expression 
To identify molecular mechanisms that prevent EAE in Asm-deficient mice, we tested 
whether Asm deficiency affects antigen-specific proliferation, which is a main requirement 
for induction of the autoimmune process during EAE. To this end we examined the 
proliferation capacity of Asm-deficient lymphocytes derived from EAE-immunized mice by 
using a 
3
H-thymidine assay. We observed no difference in MOG-induced proliferation 
between Asm-deficient and wt cells (Fig. 4.11).  
 
 
Figure 4.11 Asm deficiency does not affect proliferation of MOG stimulated lymphocytes. Using 
a 
3
H-thymidine proliferation assay, we were able to show that there was no significant difference in 
lymphocyte proliferation between wt and Asm -/- cells (p ≥ 0.05, t-test) at various concentrations of 
MOG peptide and Concanavalin A control. Values presented as mean +/- SEM for 7 wt and 7 Asm -/- 
mice from 7 independent experiments. SI = counts per minute of stimulated lymphocytes/ counts per 
minute of unstimulated lymphocytes. 
 
Furthermore, we detected neither a difference in the expression levels of beta integrins on 
lymphocytes (Fig. 4.12) nor a difference in the production of inflammatory cytokines, e.g., 
IL-2, IL-4, IL-17, IFN, or GM-CSF, (Fig. 4.13) by spleen- or lymph node–derived CD4+ or 
CD8
+
 T cells from Asm-deficient or wt mice after cell stimulation. Collectively, this data 
indicates that Asm does not mediate early T cell activation in EAE.  
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Figure 4.12 Asm deficiency does not affect expression of -1 or -7 integrin. Lymphocytes from 
wt and Asm -/- mice were isolated at day 14 p.i. and analyzed for -1 and -7 integrin cell surface 
expression using flow cytometry. The expression of these integrins was not significantly different 
between wt and Asm -/- cells derived from lymph node or spleen. Values presented as mean + SEM 
(p≥ 0.05, t-test) for 6 wt and 6 Asm -/- mice. 
 
 
Figure 4.13 Asm deficiency does not affect expression of cytokines. Lymphocytes from wt and 
Asm -/- mice were isolated at day 14 p.i. and analyzed for expression of IL-2, IL-4, IL-17, GMCSF 
and IFN using flow cytometry. The expression of these cytokines was not significantly different 
between wt and Asm -/- cells derived from lymph node or spleen. Values presented as mean + SEM 
(p≥ 0.05, t-test) for 6 wt and 6 Asm -/- mice. 
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4.5 Asm is required for -1 integrin-mediated lymphocyte-endothelial cell 
adhesion 
4.5.1 Adhesion 
Endothelial adhesion and subsequent migration of lymphocytes through the BBB is an 
important pathophysiological step in the development of EAE. To determine the adhesion and 
transmigration capability of freshly isolated lymphocytes from wt and Asm-deficient EAE 
mice, we performed in vitro adhesion and transmigration assays using the bEnd.3 endothelial 
cell line to model the BBB.  
 
Adhesion to bEnd.3 cells was 60% lower in lymphocytes from Asm-deficient EAE-
immunized mice than in wt EAE lymphocytes (Fig. 4.14). Restoration of Asm in Asm-
deficient lymphocytes re-established adhesion capability to wt levels.  
 
 
Figure 4.14 Asm deficiency reduces lymphocyte adhesion to endothelial cells. In vitro adhesion 
assays showed a significant reduction in the adhesion of Asm-deficient lymphocytes to bEnd.3 cells. 
Restoration of the Asm enzyme or treatment with the integrin activator, Mn
2+
, re-enabled lymphocyte 
adherence. Shown are means + SEM of wt control (n=10), Asm -/- No tx (n=10), Asm -/- treated with 
Mn
2+
 (n=10), and Asm -/- treated with ASMase (n=9).  *p ≤ 0.05, t-test. 
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During EAE, firm adhesion of lymphocytes to the endothelium is mainly dependent on β-1 
integrins. Likewise, β-1 integrin expression in lymphocytes is absolutely required for EAE 
induction (Bauer et al., 2009). To further prove that Asm-deficiency affects integrin activation, 
we tested whether Mn
2+
, which directly activates integrins, restores adhesion of Asm-deficient 
lymphocytes to bEnd.3 cells (Fig. 4.14). The data shows that addition of Mn
2+
 re-enabled 
Asm-deficient lymphocytes to adhere to bEnd.3 cells.  
 
4.5.2 -1 integrin clustering in ceramide rafts 
It has been previously shown that ASM-released ceramide forms large membrane platforms 
which serve to cluster receptor molecules (Gulbins and Li, 2006). Clustering of integrins has 
been shown to be a prerequisite for the proper functioning of these molecules (Grassme et al., 
2001b). To test whether ASM and ceramide mediate the clustering of -1 integrin, the most 
prominent adhesion molecule at the BBB during EAE (Bauer at al., 2009) in EAE 
lymphocytes, we prepared T cells from EAE-immunized wt and Asm -/- mice and challenged 
them with bEnd.3 cells. Through our collaboration with the group of Dr. E. Gulbins, we 
observed rapid clustering of -1 integrin in ceramide-enriched membrane platforms after 
EAE-lymphocytes contacted bEnd.3 cells (Fig. 4.15). 
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Figure 4.15 Asm induces -1 integrin clustering in ceramide-enriched membrane platforms. 
Confocal microscopy analysis of experimental autoimmune encephalomyelitis-derived lymphocytes 
from Asm deficient or wt mice after challenge with bEnd.3 cells showed clustering of -1 integrin in 
ceramide-enriched membrane platforms only in wt cells (C), whereas the receptor remained uniformly 
distributed in the plasma membrane of Asm-deficient lymphocytes (F). Panel A-C is a wt lymphocyte; 
Panel D-F is an Asm -/- lymphocyte; Panel A & D are ceramide staining; Panel B & E are -1 integrin 
staining; Panel C & F are the overlay of the first two images. 
 
In contrast, Asm-deficient T lymphocytes from EAE-immunized mice failed to form 
ceramide-enriched membrane platforms and -1 integrin clusters; -1 integrin remained 
uniformly distributed over the plasma membrane (Fig. 4.15). These findings indicate that 
lymphocyte Asm is required for -1 integrin clustering and function and the resultant T-cell 
adhesion. 
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4.5.3 Transmigration 
Based on our adhesion data, which showed a crucial role for Asm in the adhesion of 
lymphocytes to a bEnd.3 monolayer in vitro, and that Asm deficient mice were devoid of 
inflammatory infiltrates, we hypothesized that transmigration would also be reduced in Asm -
/- cells in an in vitro assay. Using the same endothelial cell line as in the adhesion assays, we 
plated Transwells to create a monolayer and applied wt or Asm -/- cells to the upper 
compartment. Analysis of cell counts from the lower compartment after 4 hours, however, did 
not reveal any significant difference between wt and Asm -/- lymphocytes (Fig. 4.16).  
 
 
Figure 4.16 Asm deficiency does reduce transmigration of lymphocytes in vitro. Transmigration 
across a bEnd.3 monolayer was not significantly different between wt and Asm deficient lymphocytes, 
or compared with non-immunized control (p ≥ 0.05, one-way ANOVA). Shown are means + SEM for 
17 wt and 12 Asm -/- mice. 
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4.6 Functional blockade of Asm with amitriptyline rescues wt mice from 
EAE and prevents lymphocyte adhesion 
As a therapeutic approach, we treated EAE-immunized wt mice twice daily with the potent 
Asm inhibitor amitriptyline (Kornhuber et al., 2010) administered i.p. at a dose of 10 mg/kg 
body weight starting on day 1 or day 10, respectively, after immunization to test whether 
amitriptyline blocks the development or clinical manifestation of the late effector phase of 
EAE, modeling the clinical situation. Due to treatment issues with the C57Bl6/J mice 
resulting in cardiac failure, we instead used SJL mice immunized with PLP for the 
amitriptyline experiments. 
 
Amitriptyline protected mice from the development of clinical EAE symptoms (Fig. 4.17). 
The number of affected mice was reduced by 51% when treatment started at day 1 and was 
even reduced by 28% when amitriptyline administration was started at day 10 after 
immunization (Fig. 4.17) indicating that amitriptyline can also block the effector phase of 
EAE development.  
 
 
Figure 4.17 Pharmacologic inhibition of Asm with amitriptyline provides protection against 
active EAE. SJL mice were actively immunized for EAE and treated with amitriptyline starting on 
day 1 (n=15) or day 10 (n=10) and compared with control (No tx) animals injected with distilled water 
(n=23). Shown is the percentage of mice with clinical symptoms. Amitriptyline treatment significantly 
reduced the number of diseased mice at day 1  (*p ≤ 0.05, t-test) but not when administered at day 10 
(n/s p ≥ 0.05, one-way ANOVA). n/s = not significant. 
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Immunohistochemical analysis of spinal cord samples confirmed the complete absence of 
leukocytes in amitriptyline-treated mice and, thus, the protective effect of amitriptyline 
administration through Asm inhibition (Fig. 4.18). 
 
 
Figure 4.18 Pharmacologic inhibition of Asm with amitriptyline reduces inflammatory 
infiltration. Immunohistochemistry staining with CD45 confirms reduced leukocyte infiltration in 
SJL mice treated with amitriptyline in spinal cord compared to control mice where significant 
infiltration is prevalent. The reduction in inflammatory infiltration corroborates the reduced clinical 
score. Shown are typical frozen sections (6 m) from a control mouse at peak of disease and an 
amitriptyline treated mouse with a clinical score of 0 taken at the same time point. 
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Adhesion analysis of amitriptyline treated wt lymphocytes showed an adhesion blockade with 
the same extent as Asm deficient lymphocytes (Fig. 4.19). The finding that amitriptyline did 
not further reduce the adhesion of Asm-deficient lymphocytes to bEnd.3 cells hints towards a 
specific targeting of Asm by amitriptyline in this context (Fig. 4.20).  
 
 
Figure 4.19 Pharmacologic inhibition of Asm with amitriptyline inhibits adhesion of wt 
lymphocytes. In vitro adhesion assays showed a significant reduction in the adhesion of wt 
lymphocytes to bEnd.3 cells when treated with 10 M amitriptyline. Shown are means + SEM of wt 
control (n=10) and wt treated with amitriptyline (n=10).  *p ≤ 0.05, t-test. 
 
 
Figure 4.20 Pharmacologic inhibition of Asm with amitriptyline in Asm deficient lymphocytes 
does not significantly decrease adhesion. In vitro adhesion assays showed no significant reduction in 
the adhesion of Asm -/- lymphocytes to bEnd.3 cells when treated with 10 M amitriptyline. Shown 
are means + SEM of Asm -/- control (n=10) and Asm -/- treated with amitriptyline (n=10).  p ≥ 0.05, t-
test. 
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5 Discussion 
MS is a chronic, demyelinating inflammatory disease of the CNS characterized by CNS-
specific immune cell infiltration from the peripheral vascular compartment, and nervous 
tissue damage, namely myelin degradation and axonal injury with subsequent neuronal loss 
(Alvarez et al., 2011). Central to this disease pathway is the adhesion of lymphocytes to 
endothelial cells and the ultimate migration of these lymphocytes from the peripheral 
circulation across the BBB. The adhesion and transmigration of lymphocytes across the 
endothelium is a complex process involving interactions between complementary adhesion 
molecules on the surfaces of lymphocytes and endothelial cells (Engelhardt and Ransohoff, 
2005). In this study, we demonstrate that genetic or pharmacological inhibition of Asm 
protects against experimental MS. Specifically, T lymphocytes lacking Asm activity either 
through genetic Asm deficiency or pharmacological Asm inhibition by administration of 
amitriptyline show a reduced clustering of integrins resulting in reduced adhesion and 
disruption of tight junctions. Thus, Asm controls key steps in the neuro-inflammatory cascade 
leading to neuronal injury during MS.  
 
5.1 Asm is essential for EAE disease pathogenesis 
In our study, we observed that the loss of Asm activity through genetic knockout served to 
protect against disease development in a mouse model of EAE in stark contrast with wild-type 
mice, which were consistently sick with significantly worse clinical outcomes. Interestingly, 
an increased production of ceramide and Asm has been found in astrocytes, particularly in the 
astrocytic endfeet, from MS lesion brain tissue (van Doorn et al., 2012) suggesting a role of 
Asm in MS pathology. We were able to show that mice lacking clinical disease 
manifestations were also devoid of inflammatory infiltration, correlating histology with 
clinical score. Our results are consistent with previous work in EAE, which showed that 
inflammation and lesion formation is strongly correlated with disease severity (Recks et al., 
2011). We were able to abolish this protection by transplanting wt bone marrow into Asm-
deficient mice. These results suggest an important role of Asm activity in the leukocyte in 
initiating EAE pathogenesis. 
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5.2 Asm activity is involved in the breakdown of the blood-brain barrier  
As a potential mechanism, we found that Asm activity is involved in the breakdown of the 
BBB during EAE. BBB breakdown has been shown to be the crucial step in MS pathology, 
preceding neurologic disease in MS patients (Kermode et al., 1990). Using the method of 
injecting Evans Blue dye (EBD) intravascularly to assess BBB integrity, we were able to 
show significant EBD leakage into the spinal cord parenchyma, both visually through 
histologic examination as well as with quantitative spectrophotometric analysis in wt mice. 
Our results are corroborated by previous studies showing a correlation between disease 
severity and degree of BBB breakdown (Fabis et al., 2007) with a more than 10-fold increase 
compared to control (non-immunized) animals. In concordance with this data, we demonstrate 
that Asm -/- mice, lacking clinical and histologic manifestations of EAE disease, had 
maintained BBB integrity with no leakage of EBD into the spinal cord parenchyma when 
assessed visually. This is in line with a recent report which found a decrease in BBB integrity 
in an in vitro endothelial cell layer treated with Asm (van Doorn et al., 2012). Furthermore, 
they were able to replicate their findings of decreased barrier function using conditioned 
medium from reactive inflammatory astrocytes (which produce increased amounts of 
ceramide and Asm) from the brains of MS patients indicating a direct role of Asm on BBB 
maintenance. 
 
The spectrophotometric analysis of spinal cord homogenate showed some leakage of EBD in 
Asm -/- mice, though significantly less than wt, despite the lack of clinical manifestations and 
visual evidence of EBD infiltration. However, this minor leakage may have been artefact of 
EBD remaining in microvessels or a direct effect of pertussis toxin administration, which has 
been shown to induce changes in permeability in an in vitro assay (Bennett et al., 2010). In 
addition to showing decreased BBB permeability in mice deficient for the Asm enzyme, we 
were also able to demonstrate a concordant decrease in destruction of tight junctions. 
Specifically, we showed vessel ZO-1 and claudin-5 abnormalities in clinically ill wt mice, and 
a preservation of these tight junctions in Asm -/- mice. ZO-1 disruption has been previously 
shown to correlate with EAE disease severity and infiltration/lesion site in mouse spinal cord 
(Bennett et al., 2010). Recently, claudin-5 disruption was also demonstrated during EAE with 
a loss of normal junctional staining patterns. The reasons for tight junction breakdown are not 
fully understood, though claudin-5 is potentially internalized as it is co-expressed with an 
autophagosomal marker (Errede et al., 2012). 
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5.3 Asm is involved in the lymphocyte adhesion pathway 
We demonstrate that Asm is important in the lymphocyte adhesion pathway during EAE. As 
an immune-mediated disease, EAE pathogenesis is highly dependent upon the interaction of 
lymphocytes with the endothelium in the central nervous system. This interaction involves 
multiple steps, including rolling, chemokine production and firm adhesion through LFA-1 and 
41 on lymphocytes binding with their endothelial counterparts, ICAM-1 and VCAM-1 
(Laschinger et al., 2002), and final transmigration of cells. Of these multiple steps, firm 
adhesion seems to be a crucial step in EAE pathogenesis. Using an in vitro adhesion assay we 
were able to demonstrate a significant reduction in adhesion in Asm-deficient T cells 
compared with wt T cells. Furthermore, in line with previous research regarding the 
importance of integrins in leukocyte adhesion, we were also able to reverse the effects of 
Asm-deficiency on adhesion by applying Mn
2+
. The divalent cation, Mn
2+
, has been 
previously shown to directly act upon LFA-1 and strongly promote binding with ICAM-1 
(Dransfield et al., 1992). Additionally, It was previously demonstrated that -4 integrin is 
important in EAE (Baron et al., 1993) and that blocking -4 with the monoclonal antibody, 
natalizumab, was able to suppress EAE in an animal model (Kent et al., 1995). Furthermore, 
natalizumab was effective in clinical studies in reducing relapse rates and disease progression 
(Polman et al., 2006).  
 
5.4 Asm activity does not affect integrin expression 
We demonstrate that integrin expression levels are not affected by Asm activity; there was no 
significant difference in -1 or -7 integrin expression between wt and Asm-deficient cells. 
This was true regardless of whether the cells were isolated from lymph node or spleen. It has 
been previously shown that -1 integrin is important in the adhesion of encephalitogenic T 
cell blasts in EAE (Laschinger and Engelhardt, 2000). In fact, the deletion of -1 integrin 
from the entire encephalitogenic T lymphocyte population was able to completely prevent 
EAE disease induction (Bauer et al., 2009). However, integrins are normally constitutively 
expressed on leukocytes but kept in a low affinity state (Carman and Springer, 2003). In order 
to firmly bind to their respective endothelial ligands, leukocyte integrins must undergo in situ 
modulation to develop high avidity (Alon and Feigelson, 2002). Our results indicate that 
integrin expression is not the key factor in the protection of Asm-deficient mice from EAE, 
however, a lack of change in expression does not rule out a change in avidity. 
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5.5 Asm affects adhesion by modulating ceramide raft formation 
In collaboration with the group of Dr. E. Gulbins, we demonstrate that clustering of -1 
integrin, increasing ligand avidity, is mediated by ceramide-enriched membrane platforms, 
which is, thus, integral to leukocyte adhesion and EAE disease pathogenesis. For a number of 
years, ceramide has been known to alter the biophysical characteristics of cell membranes. 
Ceramide molecules spontaneously fuse to form membrane micro-domains (Kolesnick et al., 
2000), which can then go on to form macro-domains, called ceramide-enriched membrane 
platforms. These ceramide-enriched membrane platforms have been shown to be essential for 
the clustering of activated receptors (Grassme et al., 2001b).  
 
We observed the formation of ceramide rafts and clustering of -1 integrin molecules within 
those rafts in activated, antigen-specific wt lymphocytes. Receptor clustering results in a high 
density of receptor molecules, consequently permitting and amplifying signal transduction by 
this receptor (Grassme et al., 2001a). The precise molecular mechanisms of ceramide-
mediated receptor clustering are unknown, however, it is hypothesized that the length of the 
transmembrane domain and the conformation of a receptor molecule may determine its ability 
to assemble in ceramide membrane domains (Zhang et al., 2009).  
 
Furthermore, we were able to demonstrate that Asm -/- lymphocytes were neither able to form 
ceramide rafts nor were they able to cluster -1 integrin molecules. This is in line with 
previous studies which showed that Asm is important in the release of ceramide in 
sphingolipid-rich rafts and, consequently, clustering of CD40 (Grassme et al., 2002b). Asm 
deficiency was also sufficient to prevent CD95 clustering and apoptosis (Grassme et al., 
2001a). These results explain why there was no change in expression of -1 integrin despite 
its previously demonstrated role in EAE development (Bauer et al., 2009). VLA-4, as well as 
LFA-1 mediated cell adhesion is regulated by receptor clustering (van Kooyk et al., 1999, 
Grabovsky et al., 2000) the absence of which, in our study, would account for the decreased 
adhesion of leukocytes and the protection from EAE. 
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5.6 Asm does not influence transendothelial migration, proliferation or 
cytokine expression 
Interestingly, we were unable to demonstrate a significant difference in transendothelial 
migration of T lymphocytes between Asm -/- and wt cells, despite the significant decrease in 
lymphocyte adhesion. In contrast with our findings, van Doorn et al. (van Doorn et al., 2012) 
recently demonstrated an increase in transmigration of monocytes across an endothelial 
monolayer when treated with Asm or a conditioned medium from reactive inflammatory 
astrocytes, which they demonstrate can produce increased ceramide and Asm. However, our 
adhesion results indicate a direct effect of the 41 integrin which has been previously shown 
to have no effect on transendothelial migration in vitro (Laschinger and Engelhardt, 2000), 
corroborating our findings. 
 
Likewise, we also found that Asm-deficiency had no effect on proliferation of T cells or 
cytokine production in lymphocytes. Bauer et al. (Bauer et al., 2009) previously demonstrated 
that -1 integrin was also not involved in T cell proliferation or production of cytokines 
during EAE. This is highly beneficial as this suggests that immunosuppression is very 
unlikely in a clinical setting when Asm activity is inhibited. Of note, Asm has been found to 
trigger release of microparticles containing IL-1 from glial cells (Bianco et al., 2009). This 
data does not necessarily contradict our findings as we assessed cytokine expression in 
lymphocytes harvested from lymph node and spleen, but did not directly assess cytokine 
expression of T cells that had adhered to or infiltrated across the BBB, nor did we directly 
assess cytokine release.  
 
5.7 Pharmacologic inhibition of Asm affords protection in EAE 
Numerous pharmacologic agents have been found to inhibit Asm activity in recent years, 
including amitriptyline, fluoxetine, sertraline, desipramine and amlodipine amongst others 
(Kornhuber et al., 2010). These drugs belong to a class of drugs known as FIASMA’s 
(functional inhibitor of acid sphingomyelinase) and are all weak bases. Specifically in our 
study we assessed amitriptyline, a well-known antidepressant that has been used in clinical 
practice since 1961 (Fangmann et al., 2008). Amitriptyline, as well as the other FIASMA 
drugs, acts by competitive inhibition of Asm, displacing the enzyme from lysosomal 
membranes, with subsequent degradation of the enzyme (Kornhuber et al., 2008). 
Consequently, amitriptyline only inhibits 60% to 80% of Asm activity (Teichgraber et al., 
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2008) and, thus, does not cause the manifestations of Niemann-Pick disease, which requires 
less than 10% of mean normal enzyme activity (van Diggelen et al., 2005). This incomplete 
inhibition of Asm activity by amitriptyline also explains why long-term treatment of patients 
with major depression does not result in severe side effects, such as immunodeficiency.  
 
Our study shows that treatment with amitriptyline significantly reduces clinical disease in a 
mouse model of EAE, which mimics our findings in mice with Asm genetic deficiency. 
Furthermore, amitriptyline significantly decreases acute adhesion of T-lymphocytes in an in 
vitro assay to the same degree as genetic knockout of the enzyme. In 2004, Göggel et al. 
showed an Asm-dependent increase in vascular permeability in isolated lung vessels treated 
with platelet-activating factor (Goggel et al., 2004). Our observation of reduced lymphocyte 
adhesion taken in conjunction with decreased vascular permeability is sufficient to explain the 
significant reduction in the development of EAE. This result would be equivalent and, in 
some cases, superior to previously described immunomodulating MS therapies, without the 
adverse side effects (Espinosa and Berger, 2011, Sorensen et al., 2012, Smith et al., 2010). 
For instance, an -4 integrin antibody when given before disease induction, was able to 
reduce the number of symptomatic mice by 75% (Yednock et al., 1992); a reduction that we 
were also able to achieve with amitriptyline. However, when the -4 integrin antibody was 
given after disease induction, the effect was diminished and served to only delay clinical 
symptoms but not prevent them (Kent et al., 1995). In contrast, when we administered 
amitriptyline 10 days after disease induction we were still able to observe a decrease in 
clinical disease expression.  
 
Therefore, given the long-term experience and clinical safety of amitriptyline and the present 
results with EAE, amitriptyline (or another FIASMA), is a very good candidate for a clinical 
study involving patients with MS. Indeed, a clinical study of MS patients treated with 
fluoxetine has already shown a reduction in MRI lesion progression, though the patients were 
only followed for 24 weeks (Mostert et al., 2008). Interestingly, FTY720 (the S1P receptor 
agonist) has been demonstrated to inhibit Asm in a manner similar to the FIASMA drug 
group (Dawson and Qin, 2011). Recently, FTY720 was also found to decrease Asm enzyme 
expression and subsequent ceramide formation in reactive human astrocytes harvested from 
MS brain lesions (van Doorn et al., 2012). FTY720 has been successfully used to treat MS 
patients (Kappos et al., 2010) and inhibits T cell infiltration in an animal model of EAE 
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(Kataoka et al., 2005). These studies are in concordance with our work and support our 
finding that Asm is an important factor in EAE pathogenesis. 
 
In summary, we demonstrate the role of Asm in a mouse model of MS. We show that Asm is 
a key enzyme in lymphocyte/endothelial cell adhesion by modulating ceramide raft formation 
and the subsequent clustering of adhesion integrins, specifically -1 integrin. Loss of Asm 
enzyme activity reduces lipid platform creation, which results in decreased integrin clustering 
leading to loss of adhesion capability. This decrease in adhesion serves to protect against EAE 
disease pathogenesis, and mice lacking the gene for Asm were consistently free of clinical 
disease and histopathologic markers of disease, including inflammatory infiltration and BBB 
breakdown. Furthermore, pharmacologic inhibition of Asm by amitriptyline was effective in 
protecting against EAE. Our study contributes to the understanding of MS pathogenesis and 
provides a good candidate for the treatment of MS in the clinical setting. 
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